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ABSTRACT 
Plasmacytoid dendritic cells (pDC) are a specialized group of circulating dendritic cells that re-
spond to viral nucleic acids with Type I IFN production as well as other cytokine and chemokines.  These 
pDC responses lead to the production of antiviral molecules and recruitment of defense cells.  During 
zoonotic B virus infection, a simplex virus of the subfamily Alphaherpesviridae, our lab has observed that 
infected individuals who succumb to infection have little-to-no-antibody or cell-mediated defenses.   To 
identify whether this was partly due to failure of pDCs to produce antiviral interferon responses or pro-
duce chemokine and cytokines, we tested the hypothesis that B virus modulates the IFN response dur-
ing zoonotic infection by blocking pDC activation and subsequent IFN signaling pathways to circum-
vent host defenses, while these pathways remain intact in the macaque hosts. We showed that human 
pDCs respond to B virus through the production of IFN-, IL-1, IL-6, TNF-, MIP-1/ and IP-10. Hu-
man pDCs co-cultured with B virus infected fibroblasts produced fewer cytokines and at lower levels. 
The macaque response to B virus was measured using PBMCs, as there are no specific reagents available 
to enrich macaque pDCs. Human and macaque PBMCs produced IFN- when exposed directly to B virus 
infected lysates. Co-cultures of PBMCs with B virus infected fibroblasts from both hosts failed to pro-
duce any significant amounts of IFN-.  To quantify the antiviral effects of PBMC induced IFN-, we 
measured B virus titers after exposure to supernatants from B virus exposed PBMCs, PBMC co-cultures 
with infected fibroblasts and exogenous recombinant Type I IFN. Our data further suggest that B virus 
resistance was not due to virus specific blockade of the Type I IFN signaling pathway because STAT-1 
was activated in infected fibroblasts when treated with Type I IFNs. These data demonstrate for the first 
time that B virus replication is unimpeded in the presence of any source of IFN- in either host cell type. 
In conclusion, this dissertation shows that the IFN- production by both hosts in response to B virus is 
similar and that IFN- treatment of B virus infected fibroblasts did not reduce B virus replication.  
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1 INTRODUCTION 
1.1 Literature Review 
1.1.1 B virus  
B virus, or Macacine herpesvirus 1, formerly known as Cercopithicene herpesvirus 1, was first 
discovered in 1934 when a doctor named Dr. William B. Brebner, was exposed to contaminated tissue 
during necropsy of a seemingly healthy macaque. Dr. Brebner showed relatively mild symptoms early in 
infection until day 10, where symptoms of central nervous system involvement were apparent. His 
symptoms became increasingly worse and he succumbed to infection 15 days after the onset of neuro-
logical involvement. Post-mortem analysis indicated death due to acute disseminated disease and en-
cephalomyelitis. Frederick Gay and Margaret Holden were one of two groups to first to identify the 
agent as viral by injecting brain and spinal cord suspensions from Dr. Brebner into rabbits. The disease in 
rabbits mimicked that of the disease in Dr. Brebner, although the rabbits succumbed in four to five days 
post-infection. They designated the agent W virus [1, 2]. Colleagues within their same department, Drs. 
Sabin and Wright, also identified the agent as a herpes virus around the same time, described the same 
disease in rabbits and designated it B virus [3]. 
B virus has a linear double-stranded DNA genome of 157 kpb [4], although previous studies prior 
to sequencing reported the length at 162.5 kbp [5] and 165 kbp [6] with 74.5% G+C composition [4]. The 
genome is surrounded by an icosadeltahedral capsid with T=16 symmetry and a diameter of about 40nm 
[7], which is surrounded by tegument proteins derived from host cell protein as well as virally encoded 
proteins. The tegument is surrounded by a double-membrane obtained from the viral glycoprotein 
studded host plasma membrane following exocytosis from the cell. The complete virus particle is ap-
proximately 160-180 nm in diameter [8].  
2 
The B virus genome is predicted to encode up to 74 proteins [4]. At least 11 of these have been 
identified as viral glycoproteins [9].  Genome sequence analysis predicted the presence of these eleven 
glycoproteins as homologs of HSV-1 and HSV-2: gL [4, 10, 11], gM [4, 11], gB [4, 11], gC [4, 11], gH [4, 
11], gG [4, 10, 12], gJ [4, 10, 13], gD [4, 10, 13], gL [4, 10], gE [4, 10], and gK [4, 11]. Recombinant pro-
teins have been produced for gB, gC, gD gE and the secreted and membrane-associated segments of gG 
[14].  
B virus enters target cells primarily by fusion as well as receptor-mediated endocytosis, similar 
to HSV-1/2 (Figure 1) [15] and I. Patrusheva, et al, unpublished raw data. B virus uses the common entry 
receptors as HSV-1/2, heparan sulfate and nectin-1, but does not use the paired immunoglobulin like 
receptor- (PILR-) or herpesvirus entry mediator (HVEM) [16]. It has also been shown that B virus can 
use other receptors in addition to these, which may shed some light on the pathogenesis of B virus in 
humans (I. Patrusheva, et al, unpublished raw data). Recent data has shown that gD is not required for B 
virus entry into certain cells types, which is a unique difference between B virus and the human simplex 
viruses to which it is closely related (I. Patrusheva, et al, unpublished raw data). Figure 1 is a working 
model demonstrating the known mechanisms of entry for HSV, some of which are shared by B virus. 
B virus, like all herpes viruses, replicates and assembles in the nucleus of infected cells. After vi-
rus entry into cells, the capsid and the tegument are transported to the nuclear pores where the DNA 
genome is released into the nucleus. Viral gene transcription takes place within the nucleus and is medi-
ated by host RNA polymerase II (pol II) along with viral and host transcription factors. As previously stat-
ed, B virus is predicted to encode about 74 genes (Table 1) [4]. B virus transcription occurs in a cascade 
fashion beginning with the production of immediate early genes (), which mediate the transcription of 
early genes) which then allow the transcription of the late genes () and DNA replication.  The imme-
diate early genes are transcribed without the production of newly formed virus proteins, so  
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Figure 1 Herpes simplex virus entry pathways 
HSV can enter cells a variety of ways depending on a number of cellular and viral factors [15]. 
  
must rely on host cell proteins and viral tegument proteins. A few examples of the immediate early 
genes include infected cell protein 0 (ICP0) which has numerous functions, but a few include modulation 
of host innate immune responses and promoting virus replication. The early genes products peak 
around 5-7 h post-infection and include enzymes and DNA-binding proteins involved in replication in-
cluding thymidine kinase (TK). Late gene transcription is dependent on virus replication and these gene 
products are primarily involved in virion assembly and include the glycoproteins and capsid proteins 
(Figure 2). The late genes can be divided into two sets of 1 and 2, depending on the timing of their 
transcription. The 1 genes are referred to as leaky late genes, as expression in minimally affected by 
inhibition of replication, while the 2 genes, or true late genes, are exclusively dependent on DNA repli-
cation as inhibition prevents their transcription [17]. There are only a small number of differences dis-
covered thus far between B virus and HSV-1 and HSV-2 [4].  Two of these differences are noteworthy 
and were discovered in our laboratory.  One is the absence of a protein that has been implicated to have 
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multiple functions, most predominantly neurovirulence, i.e., 34.5 [18, 19].  A second noted difference 
was noted due to the absence 34.5, which also plays a role in blocking the innate defenses involved 
with the activation of protein kinase RNA-activated (PKR), activated by Type 1 interferons.  B virus has 
selected for an alternative viral protein, Us11, to block this pathway, a function that can occur as a result 
of early expression of B virus Us11 [20].  HSV Us11 proteins are not expressed until late in infection [21], 
thus it appears that the novel temporal expression of B virus Us11 compensates for the lack of 34.5 
homologs.   
 
                    
Figure 2 Herpes virus replication cycle 
After entry into the cell and DNA delivery to the nucleus, the virus begins transcription of viral genes in a cascade of 
, and  genes [22]. 
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The natural hosts for B virus are members of the Macaca species of Old World monkeys. The 
disease within the natural host is relatively mild and similar to HSV-1/2 disease in humans, with occa-
sional oral or genital lesions, although acute infection, as with HSV-1/2 can also occur with no apparent 
lesions. B virus replicates in the mucosal epithelial cells, causing focal necrosis (lesion), where it gains 
access to the peripheral nerves innervating the site of injury/entry. The virus travels within a neuron via 
retrograde transport mechanism, and then establishes latency in the dorsal root or cranial ganglia.  B 
virus typically reactivates in macaques during mating season, monsoon seasons and during times of 
stress, such as transport from facilities or the wild [23, 24] (Farah-Abraham et al., unpublished raw data). 
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Table 1 Predicted Open Reading Frames of B virus 
Genetic sequence analysis of B virus E2490 has predicted a number of genes and their functions by comparison with 
HSV-1 and 2 [4]. 
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Table 1 (cont.) Predicted Open Reading Frames of B virus 
Genetic sequence analysis of B virus E2490 has predicted a number of genes and their functions by comparison with 
HSV-1 and 2 [4]. 
 
 
Upon reactivation, B virus travels via anterograde transport; and upon re-entry into the mucosal epithe-
lium begins the replication cycle again and the production of infectious virions for infection of new hosts 
or to freshen the supply of virus establishing latency in the dorsal root or cranial ganglia (Figure 3). Fatal 
B virus infection in macaques is rare and is usually seen when a monkey is immunosuppressed [24, 25]. 
Other species of monkeys are also susceptible to fatal B virus infection, when they come into contact 
with B virus shedding macaques, observed and reported in patas monkeys [26], colobus monkeys [26], 
capuchins [2], and common marmosets [27] . Infection usually occurs when these monkeys are co-
housed with infected macaques.  B virus-infected cell cultures show the characteristic feature of herpes 
viruses in that they form syncytia or multi-nucleated cells [28], particularly in epithelial cells derived 
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from non-macaque species (Figures 4 and 5). This allows for the virus to maximize productivity and limit 
the amount of cell-free virions.  
In contrast, human infection (zoonotic) is fatal in up to 80% of cases if not treated quickly 
enough following infection. B virus is the only herpesvirus thought thus far to be capable of zoonotic 
infection [29].  Humans are typically infected from a bite or scratch from an infected monkey, or from 
mucosal exposure to infected tissues or secretions. B virus replicates at the site of entry, in the periph-
ery, causing edema and swelling and the characteristic herpetic lesions in some cases. B virus enters the 
peripheral nerves innervating the site of injury or exposure, and travels to the sensory root ganglia. The 
unusual and striking characteristic with human disease is that the virus travels beyond the DRG or crani-
al ganglia, and enters the central nervous system (CNS), where it travels to the brainstem via the dorsal 
horn of the spinal cord or from the cranial ganglia, usually the ophthalmic branch of the trigeminal nerve 
in the case of eye splash exposures. Whether virus-directed destruction or immune defenses mediate 
the neurological symptoms seen with most fatal human infections remains unknown. Ascending paraly-
sis results in respiratory failure. After B virus has entered the CNS, it is often impossible to curtail the 
progression of disease. Reactivation from surviving human hosts has been observed in a few cases and 
there has been one case of observed human-to-human transmission [30]. 
9 
                               
Figure 3 Life cycle of herpes viruses in their natural hosts 
Herpes viruses replicate in the periphery and gain access to the peripheral neurons innervating the area. The virions 
are transported to ganglia where the virus can then establish latency. During reactivation, virus travels to the periph-
ery to initiate lytic infection [31]. In human B virus infection, virus continues to the CNS, leading to encephalitis, en-
cephomyelitis and death. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4 Morphology of B virus infection in monkey epithelial cells 
An electron microscopic image of monkey epithelial cell (Vero) infected with B virus at 24h post-infection. There are 
numerous budding particles on the cell surface () and the chromatin has dissipated (*) [28].  
* 
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Figure 5 B virus infection in monkey epithelial cells at different times post-infection 
The characteristic syncytia caused by B virus infection in monkey cells at different times post-infection. (1) Normal un-
infected cells, (2) at 6 h post-infection, the nucleolus begins to dissolve (), and  (3, 4) at 36 h post-infection, multi-
nucleated cells () are observed [28]. 
 
 Diagnosis of B virus infection in humans and macaques is accomplished by detection of serum 
antibodies reactive to B virus in Western blot assays and ELISA because virus is rarely shed peripherally. 
Polymerase Chain Reaction (PCR) is used for the detection of B virus DNA, and cell-culture methods for 
the detection of infectious particles, but these methods produce successful only when virus is being 
shed into a sampled site, e.g., tears, saliva, genital secretions, etc.  B virus can also be present in fomite 
contaminants. Diagnosis in macaques can be difficult, because while the virus is latent, animals may not 
have detectable levels of serum antibodies against B virus, particularly during primary infections.  A diffi-
culty in diagnosing humans is the fact that B virus antibodies cross react with HSV-1/2 antibodies, mak-
ing a positive B virus diagnosis for co-infected individuals challenging [32-34].  
2 
1 
4 
3 
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While there is no cure for B virus, rapid treatment following exposure can increase the survival 
rate to nearly 80%. Of course, thorough and immediate cleansing is the key to the prevention of B virus 
infection. Prophylaxis may have an added benefit of reducing the amount of virus that reaches the dor-
sal root or cranial ganglia [32]. After a fatal case of zoonotic infection resulting from an ocular splash in 
1997, the Center for Disease Control (CDC) recommended the use of goggles and masks for individuals 
working where macaques are or have been recently. The first few minutes after a potential B virus expo-
sure are crucial to preventing disease. The person should wash the wound or site of exposure thorough-
ly for at least 15 min. Post-exposure prophylaxis is nearly always recommended (Table 2) [32]. Currently, 
there are three available drugs for the treatment of B virus including acyclovir, valacyclovir, and 
famciclovir, with acyclovir or valacyclovir preferred for patients who have not manifested CNS symp-
toms. Gancyclovir is recommended for zoonotic infections that have progressed to CNS symptoms. The 
recommended serum levels to achieve for treatment are an IC50 of acyclovir at 18 g/ml (10-15 mg/kg 
TID) [27]; gancyclovir at 9 g/ml (5-10 mg/kg TID) [27, 32]. Acyclovir is a guanosine nucleoside analog 
that once phosphorylated by viral thymidine kinase can bind to viral polymerase, resulting in premature 
chain termination of viral DNA [35]. Valacyclovir is a pro-drug of acyclovir, which is converted in the 
body and famciclovir is the pro-drug of penciclovir [32]. Patient and physician preference dictate which 
drug is to be used as there is no difference in their efficacy. Treatment is recommended for at least two 
weeks, after which time if the patient remains asymptomatic, the drug is discontinued [32]. By the time 
effective drug concentrations are sufficient to inhibit virus replication at the site of entry, any virus re-
sulting from the exposure generally has time to enter innervating neurons. Thus, the goal of prophylaxis 
is to minimize the amount of virus that populates the dorsal root or cranial ganglia. 
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Table 2 CDC B virus Working Group recommendations for post-exposure prophylaxis for per-
sons exposed to B virus 
The CDC recommends prophylaxis after potential B virus exposure, depending on the circumstances of the situation: 
if the monkey is infected, location of the injury and how quickly treatment was administered [32].  
 
                              
1.1.2 Immune Response to herpes viruses 
The immune system is divided into two arms, the innate and adaptive immune systems. While 
for simplicity of understanding they are often considered separate systems, it is important to remember 
that the two arms communicate to help mount an effective immune response to a pathogen. Innate 
immune responses are relatively non-specific that involve a number of cells, some of which include 
monocytes, macrophages, dendritic cells, natural killer cells (NK), and neutrophils. An important consid-
eration is that other cell types, such as cells within the mucosal and skin epithelium or non-professional 
cells, also initiate innate responses, such as the production of cytokines and chemokines. Importantly, 
these early innate responses also help to activate the adaptive arm of the immune response, including T 
cells and B cells for effective control of the invading pathogen. 
Cells can recognize a foreign pathogen through distinct pathogen-associated molecular patterns 
(PAMPs) or damage-associated molecular patterns (DAMPs) by pathogen specific components or 
through products of the damage they cause, respectively. Cells have specialized systems for the detec-
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tion of PAMPs/DAMPS called pathogen recognition receptors (PRRs). PRRs include RIG I-like receptors, 
toll-like receptors (TLR), NOD-like receptors, C-type lectin receptors, and the DNA sensors. 
1.1.2.1 Retinoic acid-inducible gene I-like receptors (RLRs) 
 The retinoic acid-inducible gene I (RIG I) like receptors (RLRs) include three known cytoplasmic 
sensors: RIG-I [36], melanoma differentiation-associated gene 5 (MDA-5) [37] and laboratory of genetics 
and physiology 2 (LGP2) [38, 39], which recognize virus-derived RNA. They are adenosine-triphosphate 
(ATP)-dependent RNA-helicases that unwind dsRNA molecules. RIG-I recognizes short dsRNA structures 
and 5’triphosphate ssRNA and MDA-5 recognizes longer and more complex RNA structures [40].  HSV 
has been shown to activate the RLR pathway in mouse fibroblasts although the mechanism of action 
was unclear [41], and recent studies have implicated cross-talk with other PRRs to induce a response to 
HSV, and showed a requirement for HSV entry and replication [42]. Although the source of activation by 
dsDNA viruses is unclear with respect to cytoplasmic RNA sensors, Weber et al, have shown that after 
HSV infection, dsRNA does accumulate but the source of the RNA, whether cell-derived or from virus, is 
undetermined [43]. 
1.1.2.2 Toll-like receptors 
 The toll-like receptors (TLRs) are the best characterized PRRs and recognize a diverse array of 
PAMPs and DAMPs. Toll-receptors were first discovered in the Drosophila species and the mammalian 
homologs were later identified as a crucial sensor in innate immune responses and referred to as Toll-
like receptors (TLRs) [44]. Currently there are 12 identified TLRs in mammals of which TLRs 1-11 form 
homo- or heterodimers. Upon binding by their PAMP or DAMP, TLRs initiate signaling events that lead to 
immune gene activation and are either MyD88-dependent (Figure 6) or TRIF-dependent (Figure 7) [45]. 
TLR 1 is an extracellular PRR and recognizes lipoproteins when hetero-dimerized with TLR2. Extracellular 
TLR2 can also form a dimer with TLR6 to sense lipoprotein PAMPs, and the DAMPS: heat shock proteins 
(HSPs), the non-histone chromatin associating protein high-mobility group box 1 (HMGB1), and extracel-
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lular matrix (ECM).  TLR3 is both extracellular and endosomal and recognizes dsRNA and mRNA. TLR4 
recognizes lipopolysaccaride (LPS) and can detect a number of DAMPs, such as HMGB1, HSP, ECM, reac-
tive oxygen species (ROS), defensins, amyloid B and ox-LDL.  TLR5 detects bacterial flagellin. TLRs 7 
and 8 form a dimer in the endosome for the detection of ssRNA. TLR9 is endosomal and detects un-
methylated CpG motifs in host, viral, and bacterial DNA. Recently it is thought that TLR9 detects extra-
cellular DNA because B cells exposed to extracellular self-DNA resulted in TLR9 activation [46]. There-
fore, the route may be more important than the methylation state of the DNA. TLR 10 is non-functional 
in humans, at least as of now. Lastly, TLR11 detects profilin-like molecules and uropathogenic bacteria 
(Table 3) [45].  
Compartmentalization of TLRs allows for specialized responses to pathogens. TLRs 1, 2, 4,and 5 
are located on the cell surface, allowing for extracellular sensing of pathogens, and primarily detect 
pathogen products such as, glycoproteins or membrane structures. The TLRs 3, 7, 8 and 9 are endosomal 
allowing for intracellular sensing of pathogens by detection of bacterial or viral nucleic acids. Additional 
cell types, namely the antigen-presenting cells (APC) are capable of taking up infected or necrotic cells, 
and inducing endosomal immune responses to extracellular pathogens. 
 
Table 3 TLRs and their associated PAMPs and DAMPs 
TLRs recognize a number of PAMPs and DAMPs allowing for specialized detection and subsequent immune response 
activation [45].  
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 TLR signaling is initiated by binding of the respective PAMP or DAMP to the TLR dimers. Upon 
binding, TLRs 1,2, 7, 8, and 9 each use the myeloid differentiation primary response protein 88 (MyD88) 
dependent signaling pathway (Figure 6) [45]. TLR3/4 signaling use a toll/interleukin-1 receptor (TIR) do-
main containing adaptor protein inducing IFN- (TRIF or TICAM1)-dependent pathway (Figure 7) [45]. 
These signaling pathways may differ slightly in specialized cell types. 
 
Figure 6 MyD88-dependent TLR signaling pathway 
TLRs 1,2, and 4-9 signal through a MyD88 signaling pathway. There are multiple signaling adaptors recruited upon lig-
and binding, and many mechanisms to limit TLR activation, both cellular and pathogen mediated. The end point of 
TLR activation is increased gene expression of immune factors to recruit and activate immune responses [45]. 
 
 The MyD88 dependent pathway is initiated by binding of the PAMP to the TLR dimers, which 
then recruits the MyD88 adaptor molecule or the TIR-associated protein (TIRAP). These molecules asso-
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ciates with IL-1R associated kinases (IRAKS) and tumor necrosis factor receptor (TNFR)-associated factor 
6 (TRAF 6). This results in the activation of the canonical inhibitor of kappa light polypeptide gene en-
hancer in B cells, kinases (IKK ) and subsequent nuclear factor B (NFB) activation.  The TRIF de-
pending signaling pathway, utilized by TLR 3 and 4, is activated upon dsRNA or LPS binding leading to the 
recruitment of TRIF and TRIF-related adaptor molecule (TRAM), which then recruits TRAF family mem-
ber associated NFB activator (TANK)-binding kinase (TBK1) and IKK and interferon regulatory factor 
(IRF) 3 activation. These transcription factors then enter the nucleus to direct pro-inflammatory gene 
activation and Type I interferon production that direct specific immune responses to a pathogen [45].  
HSV has been shown to activate a number of TLRs. HSV can activate TLR2 through unknown 
mechanisms in bone marrow-derived dendritic cells [47], microglia [48], Chinese hamster ovary cells 
[49], and HEK293 cells [48, 50] transfected with TLR2. TLR2 is also know to sense several DAMPs, some 
of which include HSP60 and 70 which are upregulated following HSV infection [51, 52]. HSV-2 infection 
leads to the production of non-histone chromatin associating protein high mobility group box 1 
(HMBG1) [53] , which is a known PAMP of TLR2 [54]. TLR3 has been shown to respond to dsRNA gener-
ated in the cytoplasm following HSV infection of fibroblasts, although the source of the RNA, whether 
viral or host, is unclear. TLR3 deficient patients have a higher prevalence of HSV encephalitis, indicating 
an important role for TLR3 mediated sensing in HSV infection [55]. TLR9 is a well-known sensor for HSV 
DNA. Plasmacytoid dendritic cells, B cells and macrophages have been shown to sense HSV DNA through 
TLR9 [56-59]. Although mice lacking TLR9 show a reduction in the production of Type I IFNs, virus control 
is similar to control mice [56]. This indicates an important, however, non-exclusive requirement for TLR9 
signaling during HSV infection but appears to play a role in limiting virus spread along with TLR2 [56, 60]. 
1.1.2.3 NOD-like receptors 
Another PRR includes the nucleotide oligomerization and binding domain (NOD)-like receptors 
(NLR). There are over 20 known NLR family members, although NLRP3 is the most widely studied. 
17 
 
 
Figure 7 TRIF-dependent TLR signaling pathway 
TLRs 3 and 4 are the only TLRs to signal using the TRIF adaptor. TLR4 can also use MyD88. Activation of TLR3 by dsRNA 
leads to the recruitment of a number of cellular factors, leading to immune gene activation via NFB and IRF 3/7. 
There are a number of ways to regulate TLR3 signaling, both cellular and pathogen mediated [45]. 
 
 
These receptors are characterized by a NOD motif, but also contain a variety of other activating domains 
that are crucial for function. Once they are activated, NLRs expose effector domains that can recruit sig-
naling molecules for initiation of immune gene activation. NLRs are activated by the binding of a variety 
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of PAMPs: RNA or DNA; or damage associated molecular patterns (DAMPs): reactive oxygen species 
(ROS), cathepsin B and K+ influxes. NLR activation leads to the modulation of signaling pathways direct-
ing immune responses, such as the NFB, MAPK, the Type I IFN pathway, and activation of the inflam-
masome.  In the case of herpes viruses, varicella virus, which is the causative agent of chicken pox, acti-
vates NLRP3 through unknown mechanisms [61]. Additionally, HSV has been shown to activate the 
NLRP3 containing inflammasome at early times post-infection in human foreskin fibroblasts (HFF; Figure 
8) [62]. 
                                 
Figure 8 HSV-1 inflammasome activation of NLRP3 and IFI16 by HSV-1  
HSV-1 has been shown to activate NLRP3 through unknown mechanisms, and IFI16 though nuclear and cytoplasmic 
dsDNA. Activation of both pathways lead to initiation of the inflammasome and IL-1 gene expression, but HSV-1 
blocks mature IL-1 secretion [62]. 
  
1.1.2.4 DNA sensors 
The last PRR to be discussed here are the recently identified DNA sensors. There are currently 10 
known sensors of DNA, including DNA-dependent activator of interferon-regulatory factors (DAI or 
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ZBP1), RNA pol III, interferon-gamma-inducible protein 16 (IFI16), the DExD/H box helicases DDX60, 
DHX9, DDX41, and DHX36, Ku70, absent in melanoma 2 (AIM2) and the cyclic guanosine monophos-
phate-adenosine monophosphate (cGAMP) synthase (c-GAS), to name a few.  
DAI was the first cytoplasmic DNA sensor identified for HSV [63], although knockdown of DAI did 
not completely abrogate the response to dsDNA, indicating the presence of other sensors [64].  Recent 
studies indicate that HSV-2 can activate DAI in vaginal epithelial cells [65]. 
RNA pol III recognizes cytoplasmic dsDNA by creating RNA intermediates that can be recognized 
by RIG-I, at least in human 293T cells and in mouse cells [66, 67], but blocking RNA pol III did not inhibit 
cytokine production in human macrophages, thus the role of RNA pol III in DNA sensing is questionable 
[68].  
The molecule IFI16 is a DNA sensor that is commonly activated following HSV infection. It can 
sense nuclear DNA and can shuttle between the cytoplasm and nucleus [69-78]. It has been shown to 
detect DNA in a number of cell types including: fibroblasts [62], epithelial cells [72], human neutrophils 
[77] and dendritic cells [75]. IFI16 has been shown to detect HSV DNA in HFFs [79] and monocyte-
derived macrophages [76] and has been shown to induce inflammasome activation in HFFs at early 
times after infection, after which it is later blocked [62].  
The DExD/H box helicases bind directly to DNA nucleotides and include DDX60, DHX9, DDX41, 
and DHX36, to name a few. These helicases signal through different mechanisms depending on the hel-
icase involved. For example, the DHX36 and DHX9 signal through MyD88 [80], while many others signal 
through a complex with stimulator of interferon genes (STING) and TBK [78]. More recently another sen-
sor of DNA has been identified as c-GAS [81, 82], which can bind directly to DNA and form a complex 
with STING to mediate IFN- production. 
AIM 2 is a member of the PYHIN family, in which humans have 4 members, including IFI16. AIM2 
binds DNA within the cytoplasm by the HIN domain independent of the sequences, and interacts with 
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the apoptosis-associated speck-like protein containing a carboxy-terminal CARD (ASC) component to 
activate the inflammasome [83-85]. AIM2 has also been identified as a DNA sensor for HSV and is lim-
ited to cytoplasmic DNA [71, 84]. 
Ku70 is a part of the DNA-dependent protein kinase (DNA-PK) complex along with Ku80 [86], 
and is involved in nuclear processes such as non-homologous end-joining DNA repair, V(D)J recombina-
tion, and telomerase maintenance [87]. It has also been shown to mediate DNA sensing in the cytoplasm 
in HEK293T cells and mediates IFN  production [88, 89].  Ultimately, with all of the PRRs, the goal of 
responding to pathogens is to mount an effective immune response to limit infection and spread and it 
is no different for HSV in the natural host (Figure 9). 
 
               
Figure 9 Pathogen recognition of HSV 
HSV can be detected by many PRRs including TLRs 2,3,and 9, and the DNA and RNA sensors. The pathways associated 
with HSV-1 recognition lead to anti-viral cytokine and chemokine expression [90]. 
 
 
1.1.2.5 Innate immune cells 
Now that we understand how cells are able to sense an invading pathogen, it is important to 
understand the contribution of the many different cell types involved in innate immune responses and 
how their functions help shape an effective adaptive immune response. A few key players in innate im-
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munity include the non-professional cells, such as the endothelial or epithelial cells, which are usually 
the primary targets of infection, and the professional cells such as dendritic cells, monocytes, macro-
phages, natural killer cells, and neutrophils.  
In the case of HSV, the mucosal epithelium or skin epithelium is crucial in sending those first sig-
nals that something is wrong (Figure 10). Keratinocytes and fibroblasts are the skin cells used for in vitro 
HSV studies of primary human infection when clinical samples are unavailable. Primary cell production 
of cytokines and chemokines is crucial for mounting an initial response to a pathogen by recruiting and 
activating effector immune cells. Fluids from recurrent herpetic lesions on day 1 contained mostly IL-1, 
followed by IL-6, IL-10, IL-1 and IL-12, while on day 3, contained mostly IL-6, followed by IL-1, IL-1, 
TNF- while IL-10 levels remained unchanged. Chemokines were also produced from recurrent lesions 
and contained mostly MIP-1, followed by MIP-1 and RANTES [91].  Keratinocytes are one of the first 
sites of primary HSV replication, and despite rapid cell destruction after HSV infection, these were 
shown to be a source of IL-12, IL-10, MIP-1, MIP-1 and RANTES on day 3 after HSV infection, and IL-
1, IL-1 and IL-6 after 6 days [91]. Additional studies showed that in vitro HSV infection of keratino-
cytes increased expression of the interferons and , TNF-, G-CSF, GM-CSF, IL-3 and several growth 
factors [92], indicating an important role for these cells in sending the first signals for immune activa-
tion. Fibroblasts are the primary cells comprising the dermal layer of skin and are also a source for in 
vitro studies with HSV. Very little data exist on the cytokines and chemokines produced after infection of 
these cells. Recent studies for NLR and DNA sensor activation showed a failure of HFFs to respond to 
HSV with the production of IL-1[62], but also showed an increase in IFN- transcripts after HSV infec-
tion [79].   Additionally, recent studies in our lab showed that HFFs failed to secrete any cytokines or 
chemokines following HSV-1 infection including: eotaxin, G-CSF, GM-CSF, IFN-α2, IFN-γ, IL-10, IL-12 
(p40), IL-12 (p70), IL-13, IL-15, IL-17, IL-1α, IL-1β, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IP-10, MCP-1, MIP-
1α, MIP-1β, TNF-α, or TNF-β (M. Vasireddi et al., unpublished raw data).  
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Figure 10 The epidermal immune response to HSV-2 
HSV-2 infection initiates in the keratinocytes which respond to virus through the production of many cytokines and 
chemokines, which recruit a number of innate and adaptive immune cells [93]. 
  
Following the signals received from infected primary cells, innate effector immune cells are recruited 
into action during infection. The first cells to enter HSV lesions appear to be neutrophils. Neutrophils, 
whose primary function is to destroy pathogens through the production of large amounts of ROS and 
cytotoxic granules within the phagosomes, are specialized innate immune cells that circulate in the 
blood. More recently, neutrophils have been shown to expel nuclear complexes containing DNA and 
granular proteins, as well as LL37 called NETs, providing another means of microbial protection [94, 95]. 
Neutrophils also help shape the immune response through the production of cytokines that direct anti-
body production by B cells [96-98], can directly activate T cells through their expression of activating 
receptors [99, 100] and MHC II [100] as well as transport antigen from the dermis to the lymph nodes 
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[101-104]. Neutrophils can activate pDCs through the production of NETs [105] and coordinate with DCs 
to activate NK cells [106, 107]. Neutrophils have very tightly regulated systems for migration [108, 109] 
and the production of granules [110]. Neutrophils are well known for their ability to destroy extracellu-
lar bacteria and fungi, but more recently have been shown to play a role in anti-viral immunity to HIV 
[111] and poxvirus [112] through the production of NETs. 
 Additional cell types involved in the innate immune response to herpes viruses include macro-
phages, natural killer cells, dendritic cells, including myeloid dendritic cells, plasmacytoid dendritic cells, 
skin dendritic cells, the Langerhan cells and dermal dendritic cells. Other subsets of dendritic cells are 
present within lymphatic tissue are also important for immunity against herpes viruses. 
Adaptive immune responses are initiated through the activation signals of innate immune cells. 
B cells and T cells are the most common cell types associated with adaptive immune responses. T cells 
can be divided into a number of subsets to include CD4+ T cells, CD8+ T cells, regulatory T cells, and sup-
pressor T cells. The subsets of T cells can be distinguished by their transcription factor expression.  Typi-
cally CD4+ T cell functions are divided into multiple subsets including two of which are the T helper-1 
(TH1) or T helper-2 (TH2) responses. Their responses are called into play by the specific cytokines pro-
duced by innate cells as well as the T cells themselves, and are associated with the activation of the dif-
ferent subsets of T cells. TH1 is often referred to as the cell-mediated branch of adaptive immunity and 
usually leads to the activation of cytotoxic CD8+ T cells, which leads to cell-mediated cell death, while 
the TH2 refers to the antibody-mediated branch and typically leads to the activation of B cells for the 
production of antigen specific immunoglobulins (Igs). It is important to note that many of the other T-
cell subsets likely play additional roles at different times during infection. 
1.1.2.6 Plasmacytoid dendritic cells 
 Plasmacytoid dendritic cells are a specialized group of lymphoid-derived dendritic cells that rec-
ognize bacterial and viral genomes through their exclusive expression of TLRs 7 and 9 [113-115]. 
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Plasmacytoid dendritic cells are identified based on surface phenotypic markers, specifically CD4+, 
CD45RA+, IL3R (CD123)+, ILT3+, ILT1-, CD11c-, lineage-, BDCA-2, BDCA-4, CD4+, [116]. The primary 
function of pDCs is to produce large amounts of Type I IFNs, including 13 subtypes of IFN- and IFN- 
and Type III IFNs such as IFN-, but pDCs do not make IFN-, the only type II IFN. pDCs can also make 
tumor necrosis factor- (TNF-), IL-6, IL-1, and several chemokines such as MIP-1 , and IL-8 to 
recruit and activate a number of effector immune cells to the sites of infection [117-121]. Additionally, 
pDCs are capable of presenting antigen to T cells, although this is not their primary role. pDCs can be 
found in the skin, in peripheral blood, and in the lymph nodes [122] .  
 Plasmacytoid dendritic cells were first described in the 1950s by pathological examination of 
lymph node and splenic tissues, as cells with a plasma cell-like morphology [123]. Decades after their 
initial identification, when more advanced cell immunology assays were developed, these cells were 
designated plasmacytoid T cells [124, 125], or plasmacytoid monocytes [126], based on the cell surface 
phenotypes. In the 1980’s a very similar cell-type, with plasma like morphology, was designated as the 
natural interferon-producing cell [127], because they produced large amounts of IFNs in response to 
virus infections and they were distinct from T cells, B cells, monocytes and NK cells [127-130]. Only very 
recently, in 1997, were these cells shown to be of dendritic cell origin and were called DC2 based on 
their ability to differentiate into TH2 DCs [125]. In 1999, the natural interferon-producing cell was con-
firmed to be the same as the plasma-like DC2 and thus designated plasmacytoid dendritic cells (pDC) 
[116, 126]. 
 The pDCs exclusively express TLRs 7 and 9 to allow the detection of viral nucleic acids. A com-
monly used positive control for TLR9 activation is synthetic single-stranded DNA containing un-
methlyated phosphorothioate-linked CpG motifs (CpG; CpG ODN) [131-134]. These TLRs are endosomal, 
activated in response to foreign DNA in most cases. TLRs 7 and 9 share a signaling pathway that is medi-
ated by MyD88. Following activation, a signal transduction complex is formed in the cytoplasm and is 
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composed of many different proteins, including MyD88, IRAKs, TRAFs, and IRF7 [115, 135-137] (Figure 
11). IRF7 is constitutively expressed in pDCs, along with IRF4, and IRF8 [138], due to lack of translational 
repressors (4E-BPs) [139], and upon activation is rapidly translocated to the nucleus for IFN transcription 
initiation when TLR signaling is initiated by the early endosome. This signaling complex is also capable of 
activating the NFBs [140] and MAP kinases [141] by engagement of ligands in the late endosome to 
direct the activation of pro-inflammatory cytokine and chemokine genes and co-stimulatory molecule 
expression [134]. The constitutive expression of the IRFs allows for a rapid IFN response independent of 
the IFNR feedback that most other cells require [142]. IRF 8 amplifies the IFN response during the sec-
ond phase of IFN transcription and IRF 4 is a negative regulator of proinflammatory cytokine production 
by interacting with MyD88 [143], but does not interfere with IRF7-dependent IFN responses.  
Upon activation pDCs undergo maturation in which they downregulate IFN- and pro-
inflammatory cytokine production and up-regulate co-stimulatory molecules for antigen presentation 
and T cell activation, such as CD40, CD80, CD86, CD83, ICOS-ligand and OX40 ligand [144]. pDCs are effi-
cient activators of T cells [115, 122, 125, 145-148], although they are less efficient than the conventional 
DCs due to the short half life of MHC II on the cell surface and the rate at which they take up antigen 
[149]. pDCs have been shown to activate T cells through direct MHCII expression, but also through trans-
fer of Ag to lymph node resident DCs for cross-presentation to CD8 T cells in cutaneous HSV-1 infection 
in mice [150].  
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Figure 11 The TLR7/9 signaling pathway in pDCs 
Viral nucleic acids are taken into pDCs by endocytosis and transported to the endosomes for activation of TLR7/9. This 
pathway is mediated by MyD88 and triggers a signaling cascade that leads to a complex formation consisting of 
IRAK1, IRAK4, TRAF3/6, which activate constitutive IRF7 to induce IFN gene transcription. Additional signaling mole-
cules can then activate NFBs and MAPKs to induce pro-inflammatory cytokine production and co-stimulatory mole-
cule expression [151]. 
 
 pDCs respond robustly to HSV-1 through the production of Type I IFNs [41, 56, 57, 122], and 
thus HSV-1 is commonly used as a positive control for pDC activation and was used in the experiments 
presented in this dissertation. HSV contains numerous CpG motifs that can interact with TLR9 [152] to 
activate pDCs via TLR 9 [42, 56, 57], and independently of TLR 9 [153]. It has been shown that pDCs are 
important in in vivo studies as they are recruited to active HSV-2 lesions and are important for recruiting 
and activating T cell responses [122]. Also, antibody depletion studies in mice showed that pDCs, dis-
pensable in controlling systemic infection, were necessary for IFN- production by cytotoxic T cells. Ab-
sence of pDCs extended the time for virus clearance [150].  pDC-induced IFN- has been shown to acti-
vate HSV specific CD4+T cells in mice for the production of IFN- and IL-10 [154]. This IFN has also been 
shown to induce the migration of T cells and NK cells through the production of chemokines [58]. pDCs 
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are also important in reducing viral titers in HSV-2 infected mice since pDC depleted mice showed worse 
survival than normal mice [155]. Additional studies in mice showed that pDC depletion reduced the sys-
temic IFN- and pro-inflammatory cytokine production, and subsequent activation of NK cells and CD8+ 
T cell responses to HSV-1. But for localized infections, pDCs did not reduce the viral burden or survival in 
subcutaneous HSV-1 or intravaginal HSV-2 infection [156]. In vitro studies of human pDCs showed that 
HSV-1 activated pDCs stimulated CD4 T cells to express perforin and granzyme, and produce IL-10 and 
IFN- [157]. Also, Kittan et al. reported patients suffering from HSV retinal necrosis had reduced pDC and 
CD8 T cell numbers [158], although Moss et al. found no correlation with circulating pDC numbers and 
the clinical severity of HSV-2 infection [159]. 
Massive production of IFNs and pro-inflammatory cytokines from pDCs helps to shape both the 
innate and adaptive immune responses to pathogens.  pDC-induced IFN- and TNF- promotes auto-
crine survival as well as survival and maturation of bystander pDCs [154]. Cytokines from pDCs can ro-
bustly recruit and activate NK cells for lysis of infected cells [56, 58, 160, 161]. pDC induced cytokines 
also shape the immune response by activating monocytes to increase TLR7 expression and surface ex-
pression of pDC markers [161, 162], and can induce monocytes to produce IFN- in response to HSV 
[163] as well as induce IP-10 production from monocytes to recruit other effector cells [164]. pDCs can 
also shape the antibody response by IFN- induced expression of B cell activating factor (BAFF) on mDCs 
[165], inducing B cell differentiation into antibody secreting plasma cells through the production of IFN-
 and IL-6 [166], and can induce class-switching of plasma cells [167]. Overall, the pDCs response is im-
portant for combating pathogens through the production of IFNs and cytokines and chemokines for the 
recruitment and activation of effector immune cells, all of which contribute to the overall host response 
to a pathogen. 
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1.1.3 Type I Interferon Pathway 
Interferon was first discovered in 1957 when two researchers, Isaacs and Lindenmann, were ex-
ploring a new concept of viral interference. This was the first time a soluble factor was identified and 
shown to provide protection to uninfected cells [168]. The Type I Interferon pathway is important for 
the induction of an antiviral state within infected hosts. This pathway is initiated by a number of PRRs, 
such as TLRs, RLRs, DNA sensors, nucleic acid sensing molecules, such as RIGI, MDA5 for RNAs and DAI 
and IFIs for DNA detecting the invading pathogen, as discussed previously. Activation of the PRRs leads 
to the recruitment and activation of signaling molecules that are specific for antiviral genes to control 
the invading pathogen. The downstream activation targets differ, but ultimately activate interferon 
stimulated gene factors (ISGFs) that can direct interferon-stimulated gene (ISG) transcription. These 
genes are then transcribed and the proteins act at different stages of virus replication and gene tran-
scription. A specific gene activated through any of these pathways is type I interferons  and . There 
are five types of Type I IFNs, IFN-, IFN-, IFN-, IFN-, and IFN-Of these, IFN-and  are the main 
subtypes of interest in antiviral immunity. There are 13 subtypes of IFN-1245678,
101314,16,17,and21 in humans and only one of IFN- [169-171].These two IFNs bind to 
a common receptor, the IFNR, which is composed of two subunits of IFNR1 and IFNR2. These com-
plexes dimerize and can be bound by the different subtypes of Type I IFNs, which triggers a signaling 
cascade. The signals are mediated by a number of adaptor molecules, depending on the activating lig-
ands (Figure 12) [172]. Ultimately, these pathways culminate in the activation of interferon-stimulated 
genes, such as IFN-/, pro-inflammatory cytokines, protein kinase R (PKR), MDA-5, 2’5’oligoadenylate 
synthase (OAS), and IRFs [173]. These gene products then act by a number of mechanisms to establish 
an anti-viral state within the host. 
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Figure 12 Signaling pathways activated by the I-IFN receptor 
Signaling pathways followed by the binding of ligands for the Type I IFN receptor culminates in activation of 
the JAK/STAT pathway, leading to the recruitment of several adaptor molecules such as IRFs, which can 
then enter the nucleus to direct the transcription of many ISGs [172].   
 
For this dissertation, the focus will be on the pathway mediated by IFN-, or the Janus activated 
kinase-signal transducer and activation of transcription (JAK/STAT) pathway. IFNR1 is constitutively 
associated with tyrosine kinase 2 (TYK2) and IFNR2 is associated with JAK1 [174-176]. Upon receptor 
binding by IFN-/, JAK1 and TYK2 are transphosphorylated and then the JAKs phosphorylate the IFNR 
subunits on tyrosine residues [177, 178]. These phosphate residues allows for docking by the recruited 
STAT molecules via the src-homology domains (SH2) [174, 179].  Depending on the signals received, the 
JAK1 and TYKs can recruit several different STAT molecules. There are currently 6 STAT molecules acti-
vated after Type I IFN binding, including STATs 1-6, although expression of some isoforms are limited to 
certain cell types [174, 179-186]. Once recruited to the receptors, STATs are phosphorylated by JAKs. 
Activated STATS can form homodimers such as STAT1, STAT3, STAT4, STAT5, and STAT6 and heterodi-
mers of STAT-1/2, STAT1/3, STAT1/4, STAT1/5, STAT2/3, and STAT5/6 [179-181, 187, 188]. For STAT1 
30 
and STAT2, the activating phosphorylation occurs on a single tyrosine residue, at Y701 and Y690, respec-
tively. STAT1 is also phosphorylated at Ser 727, which is required for optimal gene transcription, but not 
for nuclear translocation [189, 190]. Activated STAT1/2 then associates with IRF9 (ISGF3 complex). The 
ISGF3 enters the nucleus and binds to interferon stimulated regulatory elements (ISRE) on DNA to direct 
ISG transcription (Figure 13) [174, 179-181, 185, 191]. Within the nucleus STATs interact with a series of 
co-activators such as p300 and cAMP-responsive element binding proteins (CREB) binding protein (CBP), 
which help to regulate chromatin remodeling for access to promoters of ISGs [192-194]. 
 
Figure 13 Classical JAK-STAT signaling pathway 
The binding of IFN- or  activates the JAK-STAT signaling pathway, leading to the activation and recruitment of STAT 
homo- or heterodimers that complex with IRF9 and enter the nucleus to bind to ISRE direct ISG transcription [194]. 
 
Herpesviruses are known to block many steps of the Type I IFN pathway. HSV can block the in-
duction of the IFN pathway by blocking protein kinase R (PKR) activation by US11 late in infection, an 
RNA binding protein [195-199], or by 34.5 early in infection forming a complex with protein phospha-
tase 1 (PP1) to reverse PKR activation [196, 200, 201]. HSV also interferes with the IFN signaling pathway 
by blocking the activation of JAK via ICP0 [201, 202], and prevents the nuclear translocation of STAT by 
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ICP27 [203]. Furthermore, US3 hyperphosphorylation of IRF3 prevents nuclear translocation [204], and 
blocks ISG mRNA induction [205], although this has recently been challenged [206]. Very recently, VP-16 
has been shown to interfere with IRF-3 mediated gene activation by disrupting the interaction of IRF3 
and the co-activator, CREB-binding protein (CBP) [207]. HSV can also block the signaling pathways in-
duced by secreted IFNs, such as preventing the phosphorylation of JAK/STATs in the IFN signaling path-
way, although this is dependent on cell type [208] as well as inducing the suppressor of cytokine signal-
ing (SOCS), which binds to JAKs to block their activation [209] to limit ISG activation against HSV. 
1.2 Research Goals 
The goals of this dissertation were to explore the interferon response within the context of the 
foreign and natural hosts to determine whether this response may correlate with the pathogenesis of 
infection, or plainly said, why macaques live, having a robust immune response and humans die with 
little-to-no defense responses. Because the interferon pathway is so crucial to the development of an 
antiviral state, either as a direct effect on infected cells or through indirect activation of effector func-
tions of immune cells, I aimed to characterize this response in both hosts. This dissertation was designed 
to test the hypothesis that B virus modulates the IFN response during zoonotic infection by blocking 
pDC activation and subsequent IFN signaling pathways to circumvent host defenses, while these 
pathways remain intact in the macaque hosts. To test this hypothesis, I first looked at the plasmacytoid 
dendritic cell response within the human host using a cell culture model system to mimic events that 
occur when B virus infects skin or mucosal cells at the site of entry. These are one of the primary target 
cells crucial for initiating the interferon response as well as for helping to shape the development of 
adaptive immunity, both of which appear to be dysfunctional during human B virus infection. Next, I ex-
plored the macaque immune response to B virus infection ex vivo to determine PBMC response to B vi-
rus, as it was not possible to isolate pDCs from macaques due to lack of specific reagents to enrich these 
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cells. Further, we studied the interferon-signaling pathway within fibroblasts, from both humans and 
macaques, to identify differences between the two host cell responses at the primary sites of infection.  
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2 MATERIALS AND METHODS 
2.1 Cells and Viruses 
B virus stock (strain E2490; passage 74; originally a gift from E. Hull) was generated by passage 
in Vero E6 cells (lot CCL-81; ATCC, Manassas, VA) in Dulbecco’s modified Eagle’s medium (DMEM; Medi-
atech, Inc; Manassas, VA) supplemented with 2% fetal bovine serum (FBS; Atlanta Biologicals, Norcross, 
GA). Virus stocks were obtained by one round of freeze/thawing at -80C and were clarified by centrifu-
gation at 1000 rpm for 10 min at room temperature. Virus titers were determined by standard plaque 
assay. Virus stocks were kept at -80C until use. All experiments conducted for this dissertation were 
done using the same stock of the P74 strain of B virus E2490. All experiments with B virus were done in a 
CDC-Registered BSL-4 laboratory in compliance with the Department of Homeland Security’s regulations 
for Select Agents, in effect during most of this project. 
Herpes simplex virus-1 (strain MacIntyre; passage 7; lot VR-539; ATCC, Manassas, VA) was gen-
erated by passage in Vero E6 cells (lot CCL-81; ATCC, Manassas, VA) in Dulbecco’s modified Eagle’s me-
dium (DMEM; Mediatech, Inc; Manassas, VA) supplemented with 2% fetal bovine serum (FBS; Atlanta 
Biologicals, Norcross, GA). Virus stocks were obtained by one round of freeze/thawing at -80C and were 
clarified by centrifugation at 1000 rpm for 10 min at room temperature. Virus titers were determined by 
standard plaque assay. Virus stocks were kept at -80C until use. 
2.2 Virus Stocks and Plaque Assay 
Virus stocks were generated in Vero E6 cells in confluent roller bottles. Cells were infected at an 
MOI of 0.01 for 48 h. For collection, the roller bottle was shaken or scraped to dislodge any remaining 
cells then transferred to a 50 ml conical tube and centrifuged for 10 min at 1000 rpm. Supernatants 
were discarded and the pellet was resuspended in 5 ml of diH20 with 2X protease inhibitor. Virus stocks 
were frozen and thawed once prior to aliquoting.  Virus stocks were stored at -80C until needed.  
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Virus titers were determined by standard plaque assay. Briefly, Vero E6 cells were seeded into 
12-well plates so that they were 90% confluent on the day of the experiment. Ten-fold serial dilutions 
were made in plain DMEM and 100 l of each dilution was added to the respective wells. Virus was al-
lowed to adsorb for 1 h at 37C at which time the lysate was removed and 1 ml of 0.8% methylcellulose 
was added to each well. Cells were cultured for 48 h at 37C. For collection, wells were washed with PBS 
until all the methylcellulose was removed and 100% methanol was added to each well for 15 min. Plates 
were dunked out, rinsed and staining with 0.1% crystal violet. Plaques were counted and final titers 
were determined. 
2.3 Rhesus Macaque Fibroblast Isolation and Maintenance 
Rhesus macaque fibroblasts were isolated from whole skin biopsies (Yerkes National Primate Cen-
ter, Atlanta, GA). The majority of skin was obtained from the back of female macaques that were eu-
thanized for other purposes and tissues were kindly provided through the tissue sharing program by the 
PI using the macaque for biomedical research. Foreskin was also obtained from male macaques, but the 
tissue was difficult to use due to contamination. The macaques were negative for SIV and B virus anti-
body. 
 Whole skin biopsies were placed in PBS and stored at 4C until cells could be isolated (no more 
than 24 h). The tissue was shaved to remove hair and cut into small pieces with a sterile scalpel. 
Throughout the process the tissue was periodically rinsed in PBS containing penicillin, streptomycin with 
anti-mycotic. The tissue was place in 0.4% Trypsin/EDTA (Mediatech, Manassas, VA) for 30 min at 37C 
with vortexing intermittently. The tissue was further cut into smaller pieces and fresh trypsin was added 
and kept overnight at 4C. The following day the tissue was resuspended with vortexing and pipetting 
through a 25 ml down to a 10 ml. Once the majority of the tissue was disassociated, the cells were fil-
tered using microfilters of 100 nm. The Rhesus Macaque Fibroblasts (RMF) were pelleted at 800 rpm 
and resuspended in DMEM with 20% FBS and 1% antibiotic/antimycotic. Depending on the cell num-
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bers, RMFs were seeded into multi-well plates or a T25 flask. RMFs were cultured until they adhered (3-
4 days) with intermittent addition of fresh medium. These were cultured until confluent and transferred 
to the next largest growth flask at a 1:2 split ratio. This was considered passage (P) two. RMFs were 
grown until a consistent split at a ratio of 1:2 was confluent in two days, which varied for each animal, 
but was achieved by approximately P5. RMFs were used immediately or frozen in 10% DMSO with cul-
ture medium and stored in liquid nitrogen. For thawing of RMFs, tubes were placed in 37C for rapid 
thaw and transferred to warm medium in a multi-well plate or T-25 at a high seeding density. RMFs 
were cultured for one to two passages before using for experiments. RMF purity and isolation was veri-
fied using immunofluorescence with fibroblasts markers vimentin and fibronectin and cytokeratin, a 
marker for keratinocyte contamination. Cells were fixed with methanol for 15 min, and blocked with 
normal goat serum. These were subsequently labeled with the primary antibodies followed by goat anti-
rabbit or mouse IgG (Sigma Aldrich, St. Louis, MO)-conjugated to the specific fluorophores, followed by 
nuclear staining with Hoescht (Invitrogen, Grand Island, NY). Cells were visualized on a Zeiss AxioVert 
200 (Zeiss, Thornwood, NY) (Figure 31). 
2.4 B Virus Kinetics in Fibroblasts 
B virus titers were determined in human foreskin fibroblasts and RMFs. Fibroblasts were grown 
to confluency in 12-well plates. Fibroblasts were infected (MOI 5) for 1 h at 37C, 5% CO2.  Samples were 
collected at 1, 4, and 24h after infection by scraping and placed into a 1.5 ml microcentrifuge tube and 
stored at -80C. Virus was quantified using a standard plaque assay (Figure 32). Additionally, to deter-
mine the amount of virus that remains cells associated, virus titers (infectious virions) were determined 
for cells and supernatants (sup+cells) and supernatants only (sup) by standard plaque assay (Figure 22). 
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2.5 Human and Macaque PBMC Isolation 
Whole blood was collected from multiple healthy volunteers by veinipuncture into Becton Dick-
inson (BD) Vacutainer tubes containing sodium heparin (BD, Franklin Lakes, NJ). Blood was collected 
with informed consent and with an approved IRB in accordance with federal and institutional policies. 
Peripheral blood mononuclear cells (PBMC) were isolated by Lymphoprep (Axis-Shield, Oslo, Norway) 
density centrifugation. Macaque blood was obtained from Yerkes National Primate Research Center 
(Grant No. RR000165) and was collected in Becton Dickinson (BD) Vacutainer tubes containing sodium 
heparin (BD, Franklin Lakes, NJ) from animals of varying ages prior to necropsy in accordance with 
Yerkes National Primate Research Center’s IACUC requirements. PBMCs were used immediately or fro-
zen in fetal bovine serum (FBS) with 10% dimethyl sulfoxide (DMSO) in cryo-containers at -80C and 
stored in liquid nitrogen. 
2.6 Plasmacytoid Dendritic Cell Isolation 
Plasmacytoid dendritic cells were isolated from PBMCs by negative selection using the Human 
Plasmacytoid Dendritic Cell Enrichment Kit (Stem Cell Technologies, Vancouver, BC). Briefly, unwanted 
cells were labeled with tetrameric antibody complexes that recognize all non-pDCs and were selected 
for using dextran-coated magnetic particles. The purity of isolated pDC was assessed by flow cytometry 
using antibodies against BDCA-2 (CD303; Miltenyi Biotec, Auburn, CA) and BDCA-4 (CD304; Miltenyi Bio-
tech, Auburn, CA). 
2.7 Western Blot Analysis 
Western blot was used to analyze protein expression in cell lysates. Briefly, cells were treated ac-
cording to the experiment and cells were lysed using Laemmli buffer (Biorad, Hercules, CA) containing -
mercaptoethanol. The collection volume depended on the experiment, but ranged from 50 l for small 
plates up to 500 l for T25. Cell lysates were boiled at 99C for 5 min, placed on ice to cool, and then 
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used immediately or stored at -80C. For most samples, a 7.5% SDS-polyacrylamide gel was assembled 
and a 5% stacking gel. Samples were loaded in 10 l volume and a standard marker was used. Gels were 
electrophoresed in running buffer for approximately two hours at 70V. Gels were transferred subse-
quently onto 0.45um nitrocellulose membranes (GE Healthcare Lifesciences, Piscataway, NJ) in transfer 
buffer either overnight at 23 V or for 1 h at 70V. Protein transfer was verified using Ponceau S. Blots 
were blocked in 5% blotto with non-fat dry milk for 1 h at room temperature. Primary and secondary 
antibodies were used according to the manufacturers instructions. Blots were visualized by addition of 
ECL substrate solution (GE Healthcare Lifesciences, Piscataway, NJ) at 1:1 concentration for 5 min fol-
lowed by exposing to film for varying times, and developed using a Kodak Series 2000A Processor (Ti-Ba, 
Inc., Rochester, NY). 
2.8 ELISA for Interferon- 
Interferon- concentrations were determined using an ELISA kit for Interferon- (MabTech, Inc., 
Mariemont, OH) according to the manufacturer instructions. Briefly, a 96-well high binding EIA/RIA ELI-
SA plate (Santa Cruz, Dallas, TX) was coated with Mt 1/3/5 antibodies at 4 ug/ml in 100 ul in phosphate 
buffered saline (PBS; MediaTech, Manassas, VA) overnight at 4C. Primary antibodies were removed, 
plates were washed and after blocking, standard dilutions of IFN- and the samples were loaded into 
the wells and incubated for 2 h at room temperature. The secondary antibodies, Mt 2/4/6 were added 
and incubated at room temperature for 1 h, followed by the addition of strepavidin and 3, 3’, 5, 5’-
tetramethylbenzidine substrate (TMB; Biolegend, San Diego, CA). The reaction was stopped with 2N 
H2S04 and the sample absorbance was read at A450nm using a BioTek Powerwave HT (Winooski, VT). A 
standard curve was generated using GraphPad PrismTM and the unknown sample concentrations were 
determined. 
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2.9 PBMC Response to B Virus 
To determine how PBMCs responded to B virus, human PBMCs were isolated from whole blood. 
In 96-well plates, 1x106 PBMCs/well were exposed to various MOIs of B virus and cultured for 18-24 h in 
RPMI-1640 containing 10% FBS and 1% antibiotic. Cell-free supernatants were collected by centrifuging 
PBMCs at 100xg for 10min. Supernatants were collected in 1% Tween/DOC and stored at -80C until use. 
Additionally, PBMCs were exposed to B virus infected fibroblasts in co-cultures. Briefly, fibroblasts were 
infected with B virus for 1 h, 37C, 5% CO2. PBMCs were added to the infected fibroblasts in equivalent 
amounts and cultured for an additional 23 h. Cell free supernatants were collected by centrifuging at 
100xg for 10 min in 1% Tween/DOC and stored at -80C until analyzed.  
2.10 Luminex Assay  
Supernatants from co-cultures of pDCs with infected HFFs and pDCs were used in a LiquipChip 
apparatus (Qiagen, Valencia, CA) for the detection of cytokines and chemokines. The kit used for analy-
sis was the MilliplexTM Map Kit Human Cytokine/Chemokine 26-Plex (EMD Millipore, Billerica, MA) which 
detects eotaxin, G-CSF, GM-CSF, IFN-α2, IFN-γ, IL-10, IL-12 (p40), IL-12 (p70), IL-13, IL-15, IL-17, IL-1α, IL-
1β, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IP-10, MCP-1, MIP-1α, MIP-1β, TNF-α, and TNF-β from each well. 
The samples were analyzed according to the manufacturers instructions. The principle of the kit is the 
use of microspheres that contain a fluorescent dye. Based on different concentrations of these dyes the 
machine can detect multiple analytes from the same well. These microspheres are coated with capture 
antibodies specific for each cytokine and chemokine. A secondary biotinylated antibody is added to the 
wells and streptavidin (SA)-PE is used as a reporter molecule. The machine collects the samples and ana-
lyzes each microsphere and quantifies the fluorescence for the identification of each analyte, followed 
by a secondary laser excitation of PE for quantification of the analyte. Standard curves and unknown 
concentrations were generated and interpolated using Milliplex Analyst software (EMD Millipore, Billeri-
ca, MA).  
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2.11 B Virus Titer Reduction Assay 
To determine if B virus was sensitive to the effects of IFN-, either from PBMCs, PBMC co-
cultures or from recombinant IFN-, we set up several experiments. First, we tested the sensitivity of B 
virus titers on cultures with supernatants from B virus-exposed PBMCs. To test this, PBMCs were cul-
tured in 96-well round-bottomed plates and exposed to B virus at an MOI 5 for 24 h. Cell-free superna-
tants were collected by centrifugation at 100xg for 10 min. Supernatants were then transferred to B vi-
rus infected fibroblasts at 1 hpi and cultured for 24 h. Well contents were scraped and stored at -80C 
until titered by standard plaque assay. 
Secondly, we determined if B virus replication was sensitive to IFN- from co-cultures with 
PBMCs. To test this, fibroblasts were infected with B virus at an MOI 5 for 1 h, in 48-well plates, at which 
time, PBMCs were added to infected fibroblasts and cultured for 23 h. The well contents were collected 
by scraping and stored at -80C. Samples were titered by standard plaque assay. 
Lastly, the sensitivity of B virus was examined when fibroblasts were pre-treated for 30 min with 
Universal Type I IFN (PBL Interferon Source, Piscataway, NJ) at varying doses. Fibroblasts were infected 
with B virus for 1 h at which time IFN was added back to the cells, and cultured for an additional 23 h. 
Samples were collected by scraping and stored at -80C. Samples were titered by standard plaque assay. 
2.12 Plasmacytoid Dendritic Cells Response to B virus 
For determination of the cytokines and chemokines produced, plasmacytoid DCs were equally 
distributed into a round-bottomed 96-well plates. Each treatment was added in 200 ul RPMI-1640 with 
10% FBS and 1% penicillin/streptomycin. As negative controls, “untreated” consisted of medium only 
and mock-infected cell lysate (MCL) was added in the equivalent amount as B virus. For a positive con-
trol HSV-1 was used at an equivalent MOI as B virus, or CpG 2216 was used at 5 g/ml or 10g/ml (Invi-
vogen, San Diego, CA). Treatments were added and cells were cultured for 24 h at 37C, 5% CO2. Cell-
free supernatants were collected by centrifugation for 10 min at 100xg. Supernatants were transferred 
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to a clean tube containing 10% Tween/DOC for a final concentration of 1% and stored at -80C until 
used. Similarly, cytokines and chemokines were measured from B virus infected HFFs co-cultured with 
pDCs. Briefly, HFFs were infected with an MOI 5 of B virus for 6 h then pDCs were added, and cultured 
for an additional 18 h. Cell-free supernatants were collected by centrifugation at 100xg in 1% 
Tween/DOC and stored at -80C. 
To determine if the dose of B virus affects the amount of IFN- produced, pDCs were cultured in 
a 96-well round-bottomed plate and exposed to increasing MOIs of B virus for 24 h. As a positive control 
for cell function, CpG 2216 was used at 5 g/ml (Invivogen, San Diego, CA). Cell-free supernatants were 
collected by centrifugation at 100xg in 1% Tween/DOC, and stored at -80C until analyzed by ELISA.  
2.13 B virus modulation of IFN signaling pathway 
To determine if B virus modulates the IFN signaling pathway, fibroblasts were grown in T25 
flasks, infected with an MOI 5 of B virus and cultured for 24h. Cell lysates were collected at 2, 4, 6, and 
24 h in 500 ul Laemmli buffer, boiled for 5 min at 99C and stored at -80C until used. Samples were run 
on a 7.5% polyacrylamide gel and transferred by electroblotting to a nitrocellulose membrane. Blots 
were blocked and probed with an antibody against phosphorylated (Y701) STAT-1 (p-STAT-1; BD Trans-
duction Laboratories, San Jose, CA) at 1:1000 and total-STAT-1 (BD Transduction Laboratories, San Jose, 
CA) at 1:1000. As a loading control, blots were probed with anti-GAPDH (Cell Signaling, Danvers, MA) at 
1:1000. 
Secondly, to examine if B virus blocks the IFN signaling pathway, fibroblasts were infected with B 
virus at an MOI 5 for 1 h, then treated with 50 U/ml of recombinant Type I IFN for 30 min. Cell lysates 
were collected in 50 ul of Laemmli buffer, boiled at 99C for 5 min and stored at -80C until used. Sam-
ples were run on a 7.5% polyacrylamide gel and transferred to a nitrocellulose membrane, and probed 
for p-STAT-1, total-STAT-1 and GAPDH, all at 1:1000.  
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2.14 Plasmacytoid dendritic cells do not support B virus replication 
B virus infection of plasmacytoid dendritic cells 
Plasmacytoid dendritic cells were infected with B virus at 10 pfu/cell. Virus was allowed to ad-
sorb for 1 h or left on the cells for 24 h in RPMI-1640 (Mediatech, Manassas, VA) supplemented with 
10% FBS (Atlanta Biologicals, Norcross, GA) and penicillin-streptomycin (Mediatech, Manassas, VA). In 
some cases, a 50 mM citrate wash was used to inactivate any remaining virus outside of the cells. The 
infections of pDC were measured by standard plaque assay and quantitative PCR (see below).  
PCR for B virus transcripts 
Quantitative real-time PCR. DNA was isolated from B virus exposed pDCs using the Easy DNA Kit (Invi-
trogen, Grand Island, NY) according to the manufacturers instructions. Herpes B virus DNA copies were 
quantified using the Topo-PC DNA vector (Invitrogen, Grand Island, NY) containing the B virus gene for 
glycoprotein B (gB;Irina Patrusheva, Viral Immunology Center, Atlanta, GA). Targeted gB was amplified 
using the following primers for B virus gB: Forward: 5’AGGTTGATGAACGTGCTGAC 3’Reverse: 
5’CGGGCTACGTGTACTTTGAG 3’. The sequence of the gB specific internal probe containing FAM-TAMRA 
was 5’ ACTCCCACCAGCTGGGTCGC 3’. The PCR was performed using an ABI Prism 7900HT (Applied Bio-
systems, Grand Island, NY). Amplification conditions were 40 cycles of: 50C for 2 min, 95C for 10 min, 
95C for 15 sec and 60C for 1 min. Standard dilutions of the gB vector were generated and unknown 
samples were interpolated from the standard curve. 
Reverse transcriptase PCR. pDCs were exposed to B virus at 2 pfu/cell and cultured for 24 h at 37C, 5% 
CO2. Total RNA was purified using the manufacturer’s protocol for the TRI reagent RT (Molecular Re-
search Center, Cincinnati, OH). To ensure DNA and RNAase removal, a DNA-free protocol (Ambion, 
Grand Island, NY) was implemented. For PCR of B virus transcripts the following primers (Sigma-Aldrich, 
St. Louis, MO) were used:  
ICP0: Forward: 5’-CTCGAGCGTGGTGGCCAT-3’ Reverse:  3’- GGGTCATCCAGAGGCCGT-5’;  
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Thymidine kinase: Forward: 5’-TGGACCTGGCCATGCTGTC-3’ Reverse: 3’-CAGCAGGTCGAGCGTCCAC-5’; 
Glycoprotein C: Forward: 5’-GGTGGAGCTGCAGTGGCTG-3’ Reverse: 3’-CACTCGAGCGCGGTGGTCA-5’ and 
-actin: Forward: 5’-GCCATGTACGTTGCTATCCA-3’ Reverse: 3’-TGGATGCCACAGGACTCCAT-5’ with the 
Superscript One Step RT-PCR system with Platinum Taq DNA Polymerase (Invitrogen, Grand Island, NY) 
on a Gene Amp PCR System 9700 (Applied Biosystems, Invitrogen, Grand Island, NY) with the following 
program: 1 cycle at 55C for 30 min for reverse transcription,  followed by denaturation for 2 min at 
94C, and amplification with 40 cycles of 15 sec at 94C, 30 sec at 60C and 1 min at 68C, followed by a 
final extension step at 68C for 5 min and then held at 4C. The amplification products were separated 
on a 1.2% agarose gel (BioRad, Hercules, CA) and visualized. 
2.15 Statistical Analysis 
Statistical significance was measured using GraphPad PrismTM (LaJolla, CA) using a two-tailed 
paired student t-test, which compares the means between repeats of experiments containing one de-
pendent variable and a minimum of two independent variables. The experiments measuring B virus ti-
ters in fibroblasts (Figures 18, 22 and 23) and in pDCs (Figure 20) were analyzed by Student’s t-test.  
Analysis of variance (ANOVA) analyses were used to measure the significance of the results from 
experiments with two or more independent variables (Figures 16, 17, 19, and 21). ANOVA analyses re-
quire at least 3 repeats and more than two independent variables. ANOVA compares the overall mean 
across the independent variables while the application of a post-hoc test generates a p-value based on 
the means between the groups. For all ANOVA analyses a post-hoc test of Newman-Keuls was applied, 
which allows comparison of the mean of each independent variable with the controls, generating a p-
value for each independent variable. All significant values were p<0.0001 (***) or p<0.05(**). Values 
that were not significant were designated with a NS. 
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3 RESULTS AND DISCUSSION 
Based on the characteristics of zoonotic B virus infection in humans, i.e., few-to-no adaptive defens-
es, we designed experiments to study deficiencies in innate immunity that may underlie the failure of 
mounting effective adaptive defenses. We elected to study pDC responses to B virus because pDCs are the 
primary source of abundant amounts of Type I interferons, the primary antiviral molecules in mammalian 
species. There are no animal models that recapitulate infection in either macaque or humans therefore; we 
designed a cell culture model system to better understand innate defenses following B virus infection. To 
utilize this model, we first collected fresh, whole peripheral blood from multiple healthy humans and isolat-
ed PBMCs by density centrifugation. It is important to point out that B virus is not viremic (detected in 
blood) and the additional of peripheral blood PBMCs was to mimic the infiltrating PBMCs from blood into 
infected tissues.  We then used a pDC isolation kit to purify pDCs from pooled PBMCs by negative selection, 
which prevented receptor-mediated activation and led to a 97% enrichment of pDCs that were BDCA-2 
(CD303) and BDCA-4 (CD304) positive (Figure 14). There are currently no available reagents for the isolation 
of pDCs from macaques so we used human pDC and human/macaque PBMC responses following exposure 
to B virus as a measure of species-specific IFN responses.  
3.1 Human plasmacytoid dendritic cell response to B virus 
Both natural and zoonotic B virus infections usually originate in the skin through a bite or a 
scratch from an infected monkey or a splash with contaminated fluids into an open mucosal site (e.g., 
eye, mouth, etc.) or external wound. The virus replicates at the site of entry within keratinocytes and 
fibroblasts, the first target cells infected. These infected cells, and possibly adjacent cells often send sig-
nals in the form of cytokines or chemokines to recruit nearby immune cells, such as plasmacytoid den-
dritic cells unless these host defenses are blocked by the virus. Plasmacytoid dendritic cells are im-
portant producers of Type I IFNs that engage innate defense activation and shape type of adaptive im-
44 
mune pathways engaged as a result of viral infections. Dendritic cells are central for the generation of an 
immune response. A characteristic of zoonotic B virus infection, which is the induction of limited, early 
and ineffective adaptive defenses, along with the knowledge of the roles of pDCs in antiviral immunity, 
led us to formulate the hypothesis that B virus blocks the production of cytokines and chemokines from 
human plasmacytoid dendritic cells (pDC). We tested our hypothesis in a human cell-culture model to 
mimic natural infection (Figure 15). We quantified pDC cytokine and chemokine production following 
pDC exposure to B virus infected cells through co-culture with these versus direct exposure to B virus 
released from infected cell lysates. B virus replication in human fibroblasts results in the fusion of infect-
ed and healthy fibroblasts, syncytial formation, to ultimately limit the release of virions, potentially limit-
ing the numbers of virions to which defense systems are exposed. 
The pDCs were isolated by negative selection from PBMCs from healthy individuals who were 
sero-negative to B virus, HSV-1 and 2, using the Human Plasmacytoid Dendritic Cell Isolation Kit (Stem 
Cell Technologies, Vancouver, BC). The isolation yielded pDCs with a purity of approximately 98% as 
measured by FACS screening for BDCA-2 and BDCA-4 positive cells (Figure 14). Due to the low concen-
tration of pDCs in peripheral blood (0.1-0.8% of PBMCs) it was necessary to pool blood from multiple 
donors.  Although pDCs could be recruited to infected lesions from blood, our experimental setup uti-
lized peripheral blood pDCs representative of infiltrating pDCs and we used pDCs numbers much higher 
(103-104 pDCs/experiment) than would be observed in natural infection (~1-2 pDCs per lesion) because 
the activity of pDCs in tissue would be below detection. We have previously shown that pDCs from dif-
ferent donors responded differently to synthetic DNA (CpG/ODN 2216) (Figure 30 in Appendix). To cor-
rect for differential responses between heterogeneous pDCs, we used two negative controls: (i) pDCs 
exposed only to culture medium to determine any basal pDC responses and (ii) pDCs exposed to unin-
fected cell lysates, which were generated in the same way as B virus stocks, designated as mock cell ly-
sate (MCL) and at least one positive control (i) HSV-1, endemic in humans, was used because it induces 
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high amounts of IFN- from pDCs and is a closely related herpes virus to B virus, and/or (ii) CpG/ODN 
2216, which is a synthetic DNA oligonucleotide that induces IFN- via TLR9.  
 
 
 
 
 
Figure 14 Human pDC purity after isolation from PBMCs. 
BDCA-2 and-4 were used as markers of pDCs within PBMCs (A) and after pDCs purification using the Stem Cell Human 
pDC Isolation Kit (B), which resulted in a purity of approximately 98% (bottom right) by FACS analysis. PBMCs contain 
approximately 1.5% pDCs prior to isolation. As a negative control, cells were left unlabeled (left squares) to rule out auto-
fluorescence. Double-labeled pDCs are shown in the right column and are positive for BDCA-4 and BDCA-2. 
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Figure 15 The experimental design to measure the pDC response to B virus 
A. Illustrates the co-culture system of pDCs with B virus infected human foreskin fibroblasts (HFFs). HFFs (2x10
4
) were exposed 
to two negative control groups (1) Medium and (2) MCL. For the test group, HFFs were infected with (3) B virus (MOI 5) and for 
a positive control (4) HSV-1 (MOI 5). All treatements were kept on HFFs for 1h, at which time the treatments were removed and 
fresh culture medium added. At 6hpi, 1x10
4
 ppDCs were added to treated HFFs and cultured an additional 18h. Supernatants 
were collected and analyzed for 26 different cytokines and chemokines. 
B. 1x10
4
 pDCs were exposed to one of four treatments to determine how pDCs respond when directly exposed to B virus cell 
lysates. As negative controls, pDCs were exposed only to (1) culture medium and or to (2) MCL (mock cell lysate) which was 
added at the equivalent amount as for the B virus treated group. The test group consisted of pDCs exposed to (3) B virus (MOI 
5) and as a positive control pDCs were exposed to (4) HSV-1 (MOI 5).  
 
 
Our first goal was to test the hypothesis that pDCs would not produce cytokines or chemokines 
after exposure to B virus via infected human foreskin fibroblasts (HFFs). Our goal was to measure the 
response of pDCs exposed to B virus infected HFFs. A pictorial of this experiment is presented in Figure 
15A. To verify that pDCs were capable of producing cytokines and chemokines, we cultured pDCs direct-
ly with B virus released from infected cell lysates and the controls as depicted in Figure 15 B. Human 
foreskin fibroblasts (HFFs) were grown to near confluency (2x104 HFFs/well) in a 96-well plate and ex-
posed to one of the four different treatments: (1) culture medium only, (2) MCL, (3) B virus (MOI 5), and 
HSV-1 (MOI 5). To evaluate that a measureable response was due to B virus, we used two negative con-
trols, medium and MCL, present in the same amounts found in B virus lysates. HSV-1 was the positive 
control because it is a closely related herpes virus endemic in humans and is known to induce robust 
amounts of IFN- from pDCs, as previously discussed. Virus was adsorbed to cells in minimal amounts of 
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medium for 1 h at 37C. Unadsorbed virus, medium, and MCL were removed from each of the respec-
tive wells in this experiment and replaced with pDC culture medium (RPMI-1640 supplemented with 
10% FBS and 1% antibiotic). The HFFs were cultured for a total of 5 h after adsorption to allow B virus to 
progress through the virus replication cycle. By this time, immediate-early, early, and some late genes 
have been expressed. At 6 hpi, the culture medium was removed and 1x104 freshly enriched pDCs were 
added in fresh medium and this co-culture was incubated for an additional 18 h. In parallel, the aliquots 
of this pool of pDCs were seeded into separate 96-well plates to measure their response to B virus re-
leased into infected cell lysates. Controls were also exposed to the same control treatments used for the 
parallel experiment. The supernatants were collected 18h after the addition of pDCs and clarified by 
centrifugation at 100xg for 10 min. Each supernatant contained tween/DOC, at a final concentration of 
1% each to ensure that any B virus present was inactivated prior to removal from the BSL-4, in accord-
ance with the CDC’s BMBL guidelines (5th Ed.) The supernatants were removed from the BSL-4 and 
stored at -80C.  
To maximize the amount of data collected from these samples, a multiplex assay was used to 
measure the pDC response to (1) B virus infected HFF in co-cultures and (2) B virus released into infected 
lysates.  The MilliplexTM Map Kit Human Cytokine/Chemokine was purchased from Millipore to quanti-
fies the levels of 26 cytokines and chemokines within each collected sample, viz., eotaxin, G-CSF, GM-
CSF, IFN-α2, IFN-γ, IL-10, IL-12 (p40), IL-12 (p70), IL-13, IL-15, IL-17, IL-1α, IL-1β, IL-2, IL-3, IL-4, IL-5, IL-6, 
IL-7, IL-8, IP-10, MCP-1, MIP-1α, MIP-1β, TNF-α, and TNF-β. The principle of the kit is the use of micro-
spheres that contain a fluorescent dye. Based on different concentrations of these dyes the Luminex 
machine can detect and differentiate multiple analytes from the same well. These microspheres are 
coated with capture antibodies specific for each cytokine and chemokine. A secondary biotinylated anti-
body is added to the wells and streptavidin (SA)- phycoerythrin (PE) is used as a reporter molecule. The 
machine collects the samples and analyzes each microsphere and quantifies the fluorescence for the 
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identification of each analyte, followed by a secondary laser excitation of PE for quantification of the 
analyte. The software supplied by Millipore was used to determine the concentration of each analyte 
based on a standard curve generated from known standards. As shown in Figure 16, pDCs co-cultured 
with B virus infected HFFs (white bars), produced significant amounts of IFN- and TNF-, but none of 
the other cytokines measured. In contrast, pDCs exposed to B virus released into infected cell lysates 
(gray bars) produced significant amounts of IL-1 IFN-IL-6, and TNF-possibly as a result of expo-
sure to unpackaged viral DNA also released into lysates. Similarly and as shown in Figure 17, pDCs co-
cultured with B virus infected HFFs produced significant levels of IP-10, whereas, pDCs directly exposed 
to B virus infected cell lysates responded with significant production of IL-8, MIP-1, MIP-1 and IP-10. 
The raw values for the cytokines and chemokines are presented for inspection in Tables 4 and 5 located 
in the Appendix. To better understand the impact of pDCs exposed during in zoonotic infection, it is im-
portant to consider the functions of the pDC produced cytokines and chemokines in relation to the re-
cruited immune cells and the potential consequences. 
IL-1is also known as fibroblast-activating factor and B cell-activating factor.  It is constitutively 
produced by epithelial cells, and can be induced in a number of cells, including fibroblasts, macrophages, 
granulocytes and dendritic cells, just to name a few. IL-1 has been shown to activate keratinocytes and 
macrophages to induce more IL-1, but also can enhance the proliferation of fibroblasts, CD4+T cells, 
induce the production of IL-2 and IL-6, activate CD8+ T cells, induce the proliferation of mature B cells 
and induce Ig production in the presence of mitogens. As shown in the top panel of Figure 17, pDCs co-
cultured with B virus infected fibroblasts failed to induce any significant amount of IL-1 (1.75 pg/ml), 
while direct exposure to B virus and the contents of lysed infected cells induced ~100pg/ml of IL-1, 
which was significant by ANOVA with a post-hoc analysis of Newman-Keuls. Our positive control, HSV-1 
infected cells co-cultured with pDCs failed to result in the production of significant levels of IL-1, 
whereas exposure of pDCs to HSV-1 released into infected cell lysates induced 2.5 times greater levels of 
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IL-1 than pDCs directly exposed to B virus released into infected cell lysates. Each of the negative con-
trols of medium and MCL failed to induce any IL-1 from pDCs exposed to lysed cells or co-cultured with 
HFFs, underscoring that the response was specific to virus and not cells, intact or lysed. These data sug-
gest that B virus presented within the context of the co-culture experiments does not induce measure-
able IL-1 production from pDCs. IL-1 production during zoonotic infection could support multiple as-
pects of the immune response to B virus by activating and inducing the proliferation of T cells and B 
cells, neither events observed in B virus infected humans.  The lack of production of IL-1 from pDCs in 
response to B virus infected HFFs implies that pDCs would fail to activate T and B cells or support the 
healing of skin at the site of infection. The positive control, HSV-1 infected fibroblasts, also failed to in-
duce any IL-1 from pDCs, indicating that IL-1 may not be an important player in simplex virus infec-
tions.  
The presence of IFN- can influence both innate and adaptive immune cells, including NK cells, B 
cells, T cells, monocytes and dendritic cells, but can also affect primary cells, such as fibroblasts that are 
permissive to infection by B virus. IFN- can turn on various and multiple anti-viral IFN-dependent gene 
pathways such as RIG-I, and MDA-5, NF-B, and induce the expression of interferon-stimulated genes 
(ISGs). pDCs provide a major source of IFN- in the context of herpes virus infections. As shown in the 
second panel of Figure 16, B virus infected HFFs co-cultured with pDCs (white bars) produced significant 
levels of IFN- at 300pg/ml, while pDCs exposed to B virus release in infected cell lysates (gray bars) 
produced 2500 pg/ml of IFN-, 8 times more than in co-cultures. In data not shown, HFFs alone failed to 
induce any IFN- after B virus infection (N. Brock, 2013 and M. Vasireddi, 2009), underscoring that pDCs 
are a source of IFN-. Our negative controls of medium and MCL, failed to induce significant amounts of 
IFN- (4 pg/ml and (14.23 pg/ml), respectively) from co-cultures of HFFs with pDCs, indicating that the 
observed responses were not attributable to cells or cellular organelles. Our positive control of HSV-1 
infected HFFs co-cultured with pDCs (white bars) resulted in the production of 450 pg/ml of IFN- while 
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pDCs exposed to HSV-1 released into infected cell lysates (gray bars) produced 5000 pg/ml of IFN- from 
pDCs, both levels which were significant relative to levels produced as a result of just co-culture or lysed 
cells when using ANOVA. The impact of IFN- produced from pDCs was explored in this dissertation in 
the context of Type I IFN signaling pathway activation and will be discussed later (Figures 25-28) and the 
effects of IFN- on the extent of B virus replication in fibroblasts (Figures 23 and 24). The extent of the 
reach and activity of the secreted IFN- needs further investigation in the context of immune cell activa-
tion.  
IL-6 is a cytokine known to induce B cell differentiation into plasma cells, supports T cell growth 
and differentiation, induces the development of macrophages, activates keratinocytes and mediates 
lymphocyte trafficking. As shown in the third panel of Figure 16, IL-6 (400 pg/ml) was produced by pDCs 
co-cultured with HFFs exposed only to medium while MCL infected HFFs co-cultured with pDCs resulted 
in the production of twice these levels (800 pg/ml). Co-cultures of B virus or HSV-1 infected HFFs with 
pDCs, designed to reflect infected skin cells in vivo in the presence of pDCs in the vicinity, produced low-
er levels of IL-6 (100 pg/ml) when compared to the negative controls. The ability of pDCs to respond was 
verified by exposing pDCs to lysed infected cells, which resulted in production of 50 pg/ml of IL-6. Our 
co-cultures of B virus infected HFFs and pDCs induced twice as much IL-6 than pDCs directly exposed to 
virus in infected lysates, most likely because both pDCs and HFFs can respond to direct B virus exposure 
with the production of IL-6.  Interestingly, HFFs treated with MCL produced 4500 pg/ml (M. Vasireddi, 
2009), while MCL treated HFFs co-cultured with pDCs produced less IL-6 at 800 pg/ml, suggesting that 
HFF co-culture with pDCs may limiting the IL-6 production by HFFs or that nucleic acids released from 
lysed cell may be an important stimulant for activation of pDCs. Over-production of IL-6 can be detri-
mental to a host, so it is likely that pDCs or other cell types may regulate excessive production of IL-6. 
The suppression of IL-6 by B virus, relative to MCL, suggests either a direct or indirect virus-specific block 
or modulation of IL-6, which would benefit B virus survival and promote virus spread. The importance of 
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IL-6 in protection against zoonotic B virus infection is likely minimal as our positive control of HSV-1, an 
endemic human herpes virus that is rarely fatal, also suppressed IL-6 production when infected HFFs 
were co-cultured with pDCs. While the impact of IL-6 during B virus infection was not explored, pDCs can 
contribute to immune responses against B virus by activating skin cells, recruiting and activating macro-
phages, driving TH2 immune responses against B virus by promoting B cells differentiation. pDCs ex-
posed to HSV-1 infected cell lysates produced IL-6 to a greater degree (5-fold) than pDCs exposure to B 
virus infected cell lysates.  IL-6 has been shown by other investigators to be critical for resistance to HSV-
1 in selected mouse strains [210]. Although the levels of IL-6 produced during virus infected co-cultures 
were similar between B virus and HSV-1, the role of IL-6 in zoonotic B virus infection remains to be in-
vestigated.  
TNF- (tumor necrosis factor or TNF), also produced by pDCs, is a highly inflammatory cytokine 
involved in the activation of many signaling pathways within both immune and non-immune cells. It is 
produced by many cell types including CD4+ T cells, NK cells, DCs, fibroblasts and endothelial cells and is 
a potent chemoattractant for neutrophils. TNF- induces the production of cytokines and chemokines 
from many cells, stimulates phagocytosis in macrophages, activates apoptosis pathways, and is the key 
mediator of sepsis. TNF-has been shown to be essential in preventing herpes simplex encephalitis in 
mice [152]. There are no data available on the production or impact of TNF- during zoonotic B virus 
infection. As shown in the bottom panel of Figure 16, pDCs responded to the presence of B virus infect-
ed fibroblasts by producing significant amounts of TNF- at 75 pg/ml (white bars). Our positive control 
of HSV-1 infected HFFs co-cultured with pDCs produced 187 pg/ml of TNF. Direct exposure of pDCs with 
B virus infected cell lysates, however, induced 406 pg/ml of TNF, indicating that pDCs were capable of 
producing greater levels when compared to those observed from co-cultures. The positive control of 
HSV-1 infected cell lysates induced 786 pg/ml, almost 2 times as much as pDCs directly exposed to B vi-
rus infected cell lysates. Our negative controls of medium (0.43 pg/ml) and MCL (0.58 pg/ml) did not 
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induce significant amounts of TNF- in co-cultures of pDCs with HFFs, confirming that the response was 
specific to virus. In data not shown, B virus infection of HFFs alone failed to produce any TNF-, confirm-
ing that production was from pDCs (M. Vasireddi, 2009). These results suggest that pDCs in the presence 
of zoonotically infected cells are a source of TNF-, which would recruit and activate neutrophils, trigger 
phagocytosis of macrophages and induce apoptosis of infected cells. Future studies in more complex cell 
co-culture models are planned for the future, and these may lead to the development of an effective 
small animal model.  
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Figure 16 Cytokines produced from B virus-exposed pDCs 
Human pDCs were isolated by negative selection from pooled PBMCs from several antibody-negative donors and 
exposed to B virus infected cell lysates or to B virus infected HFFs.  pDCs produced significant levels (P<0.0001) of 
IL-1, IFN-, IL-6 and TNF- in response to direct exposure to B virus infected lysates (gray bars), but pDCs pro-
duced significant levels (p<0.05) of only IFN- and TNF- in the presence of intact B virus infected HFFs (white 
bars). There was a significant (p<0.05) down-regulation of IL-6 from pDCs exposed to B virus infected HFFs when 
compared to MCL treated HFFs.  Statistical analysis was performed on data from triplicate samples from one experi-
ment using ANOVA with a post-hoc of Newman-Keuls **p<0.05 ***p<0.0001. Error bars represent mean of the stand-
ard error (SEM). The table shows the mean value of each cytokine and the ratio of the mean of pDC cytokine produc-
tion when directly exposed to B virus lysates divided by the mean of pDC cytokine production in response to infected 
HFFs. ND=not detected, NA=not applicable. 
 
Many cells produce chemotactic cytokines or chemokines as a form of communication, and for 
the recruitment of effector immune cells. pDCs are one of the first responders to invading viruses, so 
any chemokines produced by pDCs will help shape the immune response by directing the recruitment of 
effector cells. Therefore, we designed an experiment to measure chemokines produced by pDCs in re-
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sponse to intact B virus infected HFFs or to direct exposure to B virus infected cell lysates. We tested the 
same supernatants that we obtained for the cytokine analysis described above and had the same nega-
tive controls of medium and MCL to verify the chemokines were specific to B virus, and HSV-1 was again 
used as a positive control.  The data revealed for the first time that B virus infected HFFs fail to induce 
any significant amounts of the chemokines measured, except for IP-10. The pDCs were functional as di-
rect exposure to B virus infected cell lysates induced significant amounts of IL-8 (CXCL8), MIP-1 (CCL3), 
MIP-1(CCL4), and IP-10 (CXCL10). The lack of chemokine production by pDCs exposed to B virus infect-
ed HFFs provides a major roadblock, which can prevent the development of an efficient and effective 
immune responses, which is lacking in the fatal cases of zoonotic B virus infection. What is lost in the 
absence of each of these chemokines? To better understand, we summarize what each of these normal-
ly function to recruit. 
IL-8 or CXCL8 is a chemokine produced by mononcytes, macrophages, fibroblasts, endothelial 
cells, dendritic cells and keratinocytes, and can be induced by IL-1 and TNF-. IL-8 is a chemotactic pro-
tein that can recruit all migratory immune cells. It can activate neutrophils for the release of cytotoxic 
granules and can also influence the production of immunoglobulins from B cells. As shown in Figure 17, 
pDCs respond to B virus infected HFFs with 87 pg/ml of IL-8 production, and our positive control of HSV-
1 infected HFFs produced 89 pg/ml, but the levels were significantly less than those measured in to the 
negative controls of medium (1500 pg/ml) and MCL (2500 pg/ml) co-cultures. In contrast, direct expo-
sure of pDCs with B virus infected cell lysates produced 400 pg/ml of IL-8 and HSV-1 infected cell lysates 
induced 750 pg/ml of IL-8, which was nearly twice the levels produced by B virus exposed pDCs. These 
responses were specific to virus as both of the negative controls for direct exposure failed to induce any 
IL-8. The role of IL-8 in neutrophil activation is well known. Neutrophils play a major role in the early re-
sponse to HSV-1 infection. While there are many cells capable of producing IL-8, it is important to note 
that pDCs contribute to neutrophil recruitment and activation. Previous work in our lab has shown that 
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B virus infected HFFs fail to recruit neutrophils in experiments with transwell co-cultures, whereas HSV-1 
infected HFFs are able to recruit neutrophils under similar conditions. These results only tested the ef-
fect of one cell type, HFFs, so the data presented here suggest a more telling possibility of limited im-
munity, also observed in fatal zoonotic infections.  The failure of pDCs to produce key recruiting chemo-
kines such as IL-8 in co-cultures with infected HFFs is likely a critical step in developing immunity against 
this fatal virus and may be a target for therapeutic modulation. 
MIP-1 or (CCL3) and the closely related MIP-1 (CCL4) are chemokines involved in the recruit-
ment of immune cells such as T and B cells. They are produced by a number of cells, including macro-
phages, CD8+ T cells, B cells, neutrophils, dendritic cells, natural killer cell, keratinocytes, fibroblasts and 
many more. They are involved in recruitment of innate immune cells, in development of a TH1 response 
and in CD4+ T cell differentiation. They can also induce cytokine production from fibroblasts, specifically 
IL-1, TNF- and IL-6. As shown in the second and third panels of Figure 17, pDCs in co-culture with B vi-
rus infected fibroblasts (white bars) failed to produce any significant levels of MIP-1 or MIP-1 at 
0pg/ml and 4pg/ml, respectively. Similarly, neither negative control induced pDC production of signifi-
cant amounts of MIP-1 or MIP-1. Our positive control, pDCs co-cultured with HSV-1 infected fibro-
blasts also failed to induce MIP-1, but induced 55pg/ml of MIP-1. We know that the pDCs were func-
tional because direct exposure (gray bar) with B virus infected cell lysates resulted in the production of  
150 pg/ml of MIP-1 and 190 pg/ml of MIP-1from pDCs, and our positive control, direct exposure of 
pDCs to HSV-1 infected cell lysates, resulted in the production of 600 pg/ml of MIP-1 and MIP-1. 
These data indicate that pDCs in co-culture with B virus infected HFFs would not be able to recruit many 
different types of immune cells. Whether the levels of MIP-1 and MIP-1 produced from B virus ex-
posed pDCs are sufficient for the recruitment of immune cells requires additional experiments. 
IP-10 (CXCL10) also known as interferon gamma-inducible protein 10 is produced by a number of 
cells such as keratinocytes, lymphocytes, monocytes, dendritic cells and macrophages. Production of IP-
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10 can be induced by IFN- or TNF- and is a potent chemoattractant for monocytes, macrophages, T 
cells and DCs. Of the chemokines measured and as shown in the bottom panel of Figure 17, IP-10 was 
the only chemokine produced in significant levels (275 pg/ml) when pDCs were co-cultured with B virus 
infected HFFs. Our positive control, HSV-1 infected HFFs co-cultured with pDCs induced 300 pg/ml of IP-
10, which was nearly equivalent to pDCs co-cultured with B virus infected HFFs. Our negative controls, 
pDCs co-cultured with HFFs exposed to medium or MCL also induced IP-10, but in significantly lower 
levels at 5 pg/ml and 91 pg/ml, respectively. HFFs exposed to MCL induced half as much of IP-10 than 
with MCL treated HFFs co-cultured with pDCs (data not shown; M. Vasireddi, 2009). pDCs directly ex-
posed to B virus infected cell lysates produced robust amounts of IP-10 at 2500 pg/ml, 10 times as much 
as co-cultured pDCs, verifying that pDCs were functional. Our positive control, pDCs directly exposed to 
HSV-1 infected cell lysates produced 4000 pg/ml of IP-10, about 1.5 times more than pDCs directly ex-
posed to B virus infected cell lysates. This response was specific to B virus as both of the negative con-
trols of medium and MCL failed result in the production of induce IP-10 from directly exposed pDCs. The 
production of IP-10 was likely induced by TNF-, as both B virus and HSV-1 exposed pDCs produced high 
amounts of TNF- (406 pg/ml and 786 pg/ml, respectively), but failed to produce any detectable levels 
of IFN-. IP-10 is a potent recruiter of many innate immune cells and production by pDCs co-cultured 
with B virus infected HFFs would allow for recruitment and the development of an antiviral immune re-
sponse against B virus, but whether these levels are sufficient requires further experiments. 
57 
 
Figure 17 Chemokines produced from B virus-exposed pDCs 
Human pDCs were isolated by negative selection from pooled PBMCs from antibody negative donors and 
exposed to B virus infected cell lysates or to B virus infected HFFs.  pDCs induced significant levels 
(P<0.0001) of IL-8, MIP-1, MIP-1 and IP-10 in response to direct exposure to B virus infected lysates 
(gray bars), but pDCs only induced significant levels (p<0.05) of IP-10 in response to B virus infected HFFs 
(white bars). Statistics were triplicate of one experiment using ANOVA with a post-hoc of Newman-Keuls 
**p<0.05 ***p<0.0001. Error bars represent mean of the standard error (SEM). The table shows the mean of 
each chemokine and the ratio of the mean of pDC chemokine production when directly exposed to B virus 
lysates divided by the mean of pDC chemokine production in response to infected HFFs. ND=not detected, 
NA=not applicable. 
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3.2 HFFs in pDC co-cultures produce infectious B virus  
In an effort to explain why pDCs co-cultured with B virus infected HFFs produced fewer and lower 
concentrations of the cytokines and chemokines than pDCs directly exposed to B virus infected cell ly-
sates, we hypothesized that the amount of virus available to pDCs in the context of B virus infected HFF 
co-cultures was significantly less than that in direct exposure to B virus cell lysates.  B virus virions are 
primarily cell-associated, as observed by the ability of B virus to form syncytia in multiple cell types, in-
cluding Vero cells (Figure 5), HFFs, and rhesus macaque fibroblasts (RMFs). The fusion of infected cells 
with healthy cells is one virus strategy that helps to limit the numbers of free virions (not cell-associated) 
available for immune surveillance, but still allows virus to enter peripheral neurons, wither by fusion of 
infected cells with neuronal membranes or escape of enveloped virions. To test this, we grew HFFs to 
subconfluency in a 12-well plate and infected them with B virus (MOI 5). Unadsorbed virus was removed 
after 1h and fresh culture medium was added and cultured these for an additional 23h. To quantify the 
amount of virus released from these infected cells we collected only the supernatants from infected 
HFFs after 24 h of infection (SUP). In addition, we collected both the HFFs and supernatants to quantify 
the amount of virus that is cell-associated and released into the supernatants (SUP+CELLS) from B virus 
infected HFFs after 24h of infection. We used a standard plaque assay to quantify the amount of virus 
within each sample, which is done by creating serial dilutions of the unknown samples, adding a known 
volume of each dilution onto confluent Vero cells, overlaying with methylcellulose and culturing for 48h. 
Plaques appear as spaces due to cell death and represent individual infectious virions, which after stain-
ing with crystal violet are counted and virus titers are determined. The results were calculated and ex-
pressed as the titers for 2x104 HFFs, the same amount of HFFs that were infected in the co-culture stud-
ies. As shown in Figure 18, B virus titers in the supernatants only (HFF sup) were 1.8x104 pfu, which was 
significantly less (p<0.05) by student t-test than the nearly 10-fold greater titer of HFF and supernatants 
(HFF sup+cells) at 1.3x105 pfu. Based on these data, the amount of virus available to pDCs in co-cultures 
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with infected HFFs was less nearly 4-fold less than that amount of B virus released from lysed infected 
cells for exposure to pDCs in direct exposure or 5x104 pfu (represented by the dashed line in Figure 18). 
This reduction in virus levels correlated with significantly reduced levels of cytokines and chemokines 
produced by pDCs in co-cultures with infected HFFs. 
 
Figure 18 B virus titers in human fibroblasts 
HFFs were infected at an MOI of 10 in 12-well plates. After 24h, B virus titers in cell-free medium were measured by 
standard plaque assay to determine the amount of cell-free virus available to pDCs in the co-culture experiment de-
scribed above. HFF sup resulted in 1.8x10
4 
pfu and HFFs sups+cells resulted in 1.3x10
5 
pfu per 2x10
4
 HFFs. The dashed 
line represents the titer of B virus that pDCs were exposed to B virus infected cell lysates (5x10
4
 pfu). HFF=human 
foreskin fibroblasts, sup=supernatant, sup+cells= supernatant and infected cells. Error bars represent SEM of tripli-
cate samples. **p<0.05 using student’s t-test for comparison of the means values. 
 
3.3 IFN- from pDCs is dependent on B virus dose 
To extend our experiments from looking at the amounts of B virus produced from HFFs during 
co-culture, we wanted to determine how different doses of B virus infected cell lysates would affect IFN-
 production from pDCs. We chose IFN- as the measure of the pDC response to B virus infected cell 
lysates because pDCs are the most potent producers of Type I IFNs in response to viral nucleic acids. Our 
previous experiment showed that the titers pDCs were exposed to in co-culture with B virus infected 
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HFFs were about 4 times lower than the titers of B virus released from infected cell lysates. Based on 
these data we hypothesized that pDC-induced IFN- correlated directly with virus dose to which these 
were exposed. To determine the effect of virus dose on the ability of pDCs to produce IFN-, freshly iso-
lated pDCs from pooled PBMCs collected from seronegative donors were exposed to B virus at 2, 5, 10 
and 20 pfu/cell. To ensure that the pDCs were responsive to B virus two positive controls were used, ie., 
HSV-1 at 5 pfu/cell and CpG 2216 at 5g/ml. The pDCs were seeded in 50ul of culture medium into 96-
well round-bottomed plates and each treatment was added in 150ul of culture medium. pDCs were cul-
tured at 37C, in a 5% CO2 humidified incubator, and at 24h cell-free supernatants were centrifuged at 
100xg  for 10min to remove cells and debris and tween/DOC was added to a final concentration of 1% to 
inactivate virus. Supernatants were stored at -80C until analyzed by ELISA for IFN- using the Human 
IFN- pan ELISA Development Kit (HRP) (MabTech, Cincinnati, OH). This kit detects 11 of the 12 subtypes 
of IFN- using a sandwich ELISA technique with a capture antibody and a detection antibody conjugated 
with horseradish peroxidase (HRP). Serial dilutions of a standard provided with the kit allowed for gen-
eration of a standard curve and unknown IFN- concentrations were interpolated using RIA 
Spline/LOWESS in GraphPad PrismTM. As shown in Figure 19, the pDCs responded to B virus released 
from the infected cells during the course of infection with the production of IFN- although it was in-
versely correlated to the dose of B virus. Both of our positive controls verified that the pDCs were re-
sponsive by producing IFN- in response to HSV-1 infected cell lysates and CpG 2216 with 33 fg/cell and 
42 fg/cell, respectively. The pDCs exposed to B virus released from infected cell lysates at 2 pfu/cell (or 
2x104 pfu) produced 33.5 fg/cell of IFN-, while pDCs exposed to B virus released from infected cell ly-
sates at 5 pfu/cell (6x104 pfu) produced 28 fg/cell of IFN-, while high MOIs of B virus released from in-
fected cell lysates at 10 pfu/cell (1.2x105 pfu) and 20 pfu/cell (2.4x105 pfu) failed to induce significant 
amounts of IFN- at 4 and 5 fg/cell, respectively. Neither of the two negative controls, cells exposed to 
medium or MCL (at the protein equivalent to BV 20 pfu/cell), produced any IFN-, indicating that the 
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IFN- produced was a specific response to virus. This result was unexpected because independent stud-
ies with HSV-1 have shown that the more virus, the greater the amount of IFN- pDCs produce, indicat-
ing that high MOIs of B virus may high MOIs of block or overwhelm pDC IFN- production. These data 
support our hypothesis that IFN- production by B virus exposed pDCs correlates inversely with the 
amount of virus used to expose pDCs, surprisingly. Based on these data and the data shown in Figure 18, 
the pDCs in co-cultures with B virus infected HFFs (1.8x104 pfu) should produce similar amounts of IFN- 
as pDCs in direct exposure to B virus infected cell lysates (5x104 pfu) as there was no significant differ-
ence of IFN- produced from pDCs exposed to 2 or 5 pfu of B virus, both of which had significantly high-
er production of IFN- than pDCs exposed to MCL (Figure 19). To explain the drastic reduction of IFN- 
production from pDCs in co-cultures when compared to pDCs directly exposed to B virus infected cell 
lysates, we considered the quality of virus within the virus lysates as these virions are likely surrounded 
by the nuclear or Golgi membranes whereas the virions released from infected cells in co-cultures would 
be surrounded by plasma membranes acquired when virions egress out of infected cells by exocytosis. 
Another possible explanation for the increase of IFN- in pDCs directly exposed to B virus infected cell 
lysates is that these contain free viral DNA that is available for the pDCs to endocytose and activate TLR9 
dependent IFN- production. There is likely to be very little free DNA in the co-culture system, as only 
intact virions would be released with the DNA protected within the enveloped capsid.  Future studies 
are needed to fully understand the mechanism of a differential response between B virus infected cell 
lysates and the B virus virions produced from infected HFFs in co-cultures.  
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Figure 19 IFN- production from pDCs is inversely correlated to virus within infected cell ly-
sates  
pDCs were isolated by negative selection from pooled, fresh PBMCs obtained from seronegative donors and were distrib-
uted equally into wells of a 96-well plate. pDCs were exposed to B virus in infected cell lysates with titers ranging from 2-
20 pfu/ml, as determined by standard plaque assay. pDCs were cultured for 24h and cell-free supernatants were collected 
and tween/DOC, added to a final concentration of 1%. IFN- levels were determined using ELISA. As negative controls, 
medium treated pDCs and MCL treated pDCs, at a level equivalent to BV 20 pfu, were used. As positive controls, pDCs 
were exposed to HSV-1 at 5 pfu/cell and pDCs were exposed to 10ug/ml of CpG 2216. **p<0.05, NS=not significant. 
ANOVA was used to analyze results along with Newman-Keuls post hoc test for pair comparisons. 
3.4 pDCs do not support productive B virus replication 
We showed that pDCs exposed to high titers (>10 pfu/ml) of B virus fail to produce significant 
amounts of IFN-(Figure 19). The viability of pDCs after B virus exposure was unchanged for all titers 
(data not shown, nor were any cytopathic effects (CPE) apparent by microscopic analysis. Based on the 
reduction in IFN- production from pDCs after exposure to high titers of B virus from lysed infected 
cells, we hypothesized that B virus infects pDCs, perhaps abortively since no CPE was observed. To test 
this hypothesis, we exposed purified pDCs to B virus infected cell lysates (MOI 10) in 50ul in medium and 
cultured for 1h at 37C, 5% CO2 to allow for adsorption. After 1h, 150ul of medium was added and pDCs 
were cultured for an additional 23h. To accurately quantify any changes in B virus titers after 24h, input 
virus used to infected pDCs along with harvested supernatants were stored at -80C for analysis. Sam-
ples were freeze-thawed two times prior to titering by standard plaque assay on Vero cells. As shown in 
Figure 20 Box A, the titer of B virus in pDCs after 24h was 2x105 pfu/ml while the input titer was 7x105 
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pfu/ml at 1hpi. The reduction of virus after 24h was not significant by paired student t-test, but clearly 
shows that pDCs do not support productive infection. This slight reduction in titer was expected because 
dendritic cell can endocytose and destroy virus particles. 
Prior to entry, B virus attaches to the surface of the cell via specific receptors. This stage of virus 
infection is referred to as adsorption in which virus particles are bound to receptors but have not en-
tered the cells. To determine if the titers from pDCs at 24h were due to replicating virus, or because vi-
rus particles were bound to the surface and had not entered the pDCs, we modified the experiment to 
include a 50mM citric acid wash, which inactivates any bound virus particles that have not entered the 
pDCs.  The same experimental setup was used except with the addition of a citric acid wash for 10min 
after the 1h adsorption step. pDCs were washed twice prior to re-suspension in 200ul of medium and 
incubated at 37C for 23h and titers were quantified by standard plaque assay. As previously, an input 
titer was collected at 0hpi, upon the addition of B virus to the pDCs. As shown in Figure 20 B, the titers in 
pDCs after 24h was reduced to zero and the input titers were 2x105 pfu/ml. These data indicate that B 
virus failed to replicate within pDCs and the titers previously observed at 24hpi, were likely adsorbed 
virus particles that failed to enter cells, remaining bound to the pDC surface.  
To further investigate whether pDCs support early events of virus infection and subsequent viral 
DNA replication, we quantified B virus replication by measuring B virus DNA copy numbers. To do this, 
we exposed pDCs to B virus (MOI 10) for 1h at 37C, in a humidified 5% CO2 incubator. After adsorption, 
unattached virus was removed by centrifugation at 400xg for 10 min. pDCs were re-suspended in 200ul 
of medium and incubated for an additional 23h, after which and cells and supernatants were collected 
in an equal volume of Solution A provided in the Invitrogen DNA Isolation Kit, and DNA was isolated ac-
cording to the manufacturer instructions. The gene encoding glycoprotein B (gB) was amplified as a 
marker of DNA replication as the greater the numbers of viral genomes replicated, the more copies of 
gB DNA. Quantitative real-time PCR was used to assess the numbers of gB DNA copies present within B 
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virus exposed pDCs, both in our input collected at 1hpi and output 24hpi. The gB gene was amplified 
using forward and reverse primers and detected using the internal sequence specific probe of FAM-
TAMRA. To quantify the gB copy numbers in pDCs exposed to B virus, a standard curve was generated 
using known concentrations of plasmids containing the gB gene. As shown in Figure 20C, the number of 
gB DNA copies in pDCs at 24h was 3.5x108 and in pDCs at 1h was 2x108. The increase in DNA copy num-
bers at 24h was not significant by paired student t-test further confirming that B virus does not produc-
tively infected pDCs. 
In all of the experiments so far we have measured late stages of viral infection, either intact viri-
on production (plaque assay) or DNA replication (gB DNA). Presumably in the absence of viral DNA repli-
cation, early events post-infection have been blocked to some extent. To determine whether B virus 
abortively infects pDCs, we used a standard reverse-transcriptase PCR to measure viral gene expression 
at throughout infection. To do this, we exposed pDCs to B virus (MOI 2) for 2h, 4h, or 6h at 37C, in a 
humidified 5% CO2 incubator. Because we were amplifying RNA transcripts, it was not necessary to re-
move virus after adsorption. pDCs were incubated for the respective times and cells were pelleted by 
centrifugation at 400xg for 10min. The cell pellets were resuspended in 200ul Tri-Reagent and RNA was 
isolated according to the manufacturers instructions. A One-Step reverse transcriptase PCR was con-
ducted to convert RNA into cDNA, then using specific primers for B virus genes of immediate-early 
(ICP0), early (TK) and late (gC) were amplified. Amplification samples were electrophoresed on a 1.5% 
acrylamide gel containing ethidium bromide for DNA detection. As a positive control, we used HFFs in-
fected for 24h with B virus (MOI 10) to confirm transcript detection. A negative control of water was 
used to detect contamination.  ICP0 is an immediate-early (IE) gene and during productive infection the 
expression reaches peak levels at 2-4hpi. As shown in Figure 20D, ICP0 gene expression in B virus ex-
posed pDCs was restricted, as a very light band was visible at 4 and 6hpi, but was not near the intensity 
of our positive control. Thymidine kinase (TK) was used as a measure of early gene expression, which 
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during productive infection peaks around 6hpi. At no time point in B virus exposed pDCs was TK gene 
expression detected, but it was present in the positive control. Lastly, gC was used as measure of late 
gene expression. We expected to see no gC transcripts since we did not detect any viral replication (gB 
DNA) or infectious virions (plaque assays) and as expected we did not see gC transcripts in B virus ex-
posed pDCs. These data indicate that pDCs do not support productive replication of B virus and infection 
is abortive at the IE stage of the B virus life cycle. Combined, all of these data confirm that B virus does 
not productively infect pDCs, since B virus titers are not increased after 24h (Figure 20A and B), that B 
virus gB copy number do not increase significantly after 24h (Figure 20C), and that early and late B virus 
genes are not expressed (Figure 20D). Based on these data, we can conclude that the lack of IFN- pro-
duction from pDCs exposed to high titers of B virus was not due to virus replication.  
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Figure 20 pDCs do not support productive B virus infection 
A. pDCs were cultured with B virus (MOI 10) for 0 and 24h and B virus titers were measured by standard plaque assay. 
B virus titers were not reduced significantly within 24hpi.  
B. pDCs were cultured with B virus (MOI 10) for 1h, then washed with citric acid and cultured for 23h and B virus titers 
were measured by standard plaque assay. B virus titers were reduced to zeroafter 24h. 
C. pDCs were cultured with B virus (MOI 10) for 1h, unadsorbed virus was removed and cultured for 24h. DNA was 
purified and qRT-PCR was used to measure gB DNA copy numbers, which were not significantly increased after 24h. 
D. pDCs were cultured with B virus (MOI 2) for 2, 4, and 6h. RNA was isolated from cell pellets. B virus transcript 
expression was detected using reverse-transcriptase PCR and run on a acrylamide gel. A positive control of B virus 
infected HFFs were used. NS=not significant. 
 
3.5 Macaque and human PBMCs fail to produce IFN- in response to B virus infected fibroblasts  
Understanding the role of individual immune cell types is important for defining direct effects of 
virus infection, but there are many indirect effects mediated by the interplay with and between other 
defense cells. The pDCs are a specific subset of dendritic cells that as we have shown in Figures 16 and 
17, respond to B virus infected fibroblasts by producing IFN-, TNF- and IP-10. We have reviewed how 
each of these molecules impacts other defense cells. The levels of each is limited, however, when com-
pared to direct exposure to B virus infected lysates after which human pDCs produced significantly more 
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IFN-, TNF-, and IP-10, as well as IL-1, IL-6, IL-8, and MIP-1/.  The restriction of cytokine production 
in human pDCs exposed to infected cells was not due to limited virus exposure due to syncytial for-
mation in fibroblasts, because we have shown that titers were similar in the supernatants of co-cultures 
and infected cell lysates (Figure 18) or due to B virus infection of pDCs (Figure 20), which we have shown 
is non-productive. One of our original purposes of the research presented in this dissertation was to 
compare the natural and foreign host response to B virus in relationship to role(s) of pDCs. Macaques 
are the natural host for B virus and the data available on how they respond to B virus is extremely lim-
ited. To contribute to the overall knowledge of the macaque response to B virus, we explored the ma-
caque pDC response to B virus, however, pDC studies in macaques are difficult due to limited availability 
of blood and a lack of pDC isolation reagents and experimental infections require BSL-4 facilities.  To 
measure the pDC response to B virus in macaques using our cell culture model, we measured IFN- pro-
duction from macaque PBMCs exposed to B virus infected cell lysates and compared these data to the 
IFN- production from pooled human PBMCs (Figure 21) and human pDCs (Figure 19) exposed to B virus 
similarly. Because there are no available reagents for the isolation of macaque pDCs, and because ma-
caque PBMCs contain similar numbers of pDCs as humans [211], we used IFN- production from human 
PBMCs (Figure 21) to correlate the amounts of IFN- produced from pDCs (Figure 19) in macaque 
PBMCs. Human pDCs produced about 30 fg/cell of IFN- when exposed to an MOI of 5 (Figure 19), and 
assuming that pDCs are 0.1% of total PBMCs, the PBMCs made approximately 46 pg/ml (46,000 fg/ml; or 
46 fg/pDC; Figure 21), which was nearly equivalent to the IFN- produced by purified pDCs. These data 
support numerous observations that pDCs produce the majority of IFN- in spite of the fact that they 
comprise less than 0.1-0.8% of the PBMCs. Based on these data, IFN- production from macaque PBMCs 
was used to correlate pDC cytokine production in macaques. The additional IFN- produced from B virus 
exposed human PBMCs can be attributed to other cell types that make IFN- such as myeloid dendritic 
cells, but we did not explore these specific sources of IFN- in our studies. The percentage of immune 
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cell types in PBMCs varies depending on individual immune responses. Whole blood contains leukocytes 
(immune cells), erthrocytes (red blood cells, RBC) and platelets. Ficoll-Density Centrifugation allows the 
separation of leukocytes from other blood products. Leukocytes comprise approximately 0.1-0.2% of 
blood cells. Of these leukocytes, T cells make up approximately 7-14%, B cells make up 1-7%, NK cells 
are 1-6%, myeloid cells, which include DCs, make up 53-86% and monocytes make up 2-12%. The granu-
locytes (35-80%) are typically removed from the leukocyte population during gradient centrifugation as 
they pellet with RBCs and platelets. We measured IFN- production from macaque PBMCs following 
direct exposure to B virus infected cell lysates and in co-cultures with B virus infected RMFs. Based on 
the characteristic of the rapid and robust induction of neutralizing antibodies in macaques after B virus 
infection, we hypothesized that B virus infected macaque co-cultures would induce robust amounts of 
IFN- from PBMCs, while human co-cultures would be restricted.  
Rhesus macaque fibroblasts were not commercially available at the time of these studies, so in 
order to test the macaque response we first had to establish and characterize a rhesus macaque fibro-
blast cell line from whole skin biopsies obtained from Yerkes Primate Center. We designate these are 
rhesus macaque fibroblasts or RMFs. The methods for isolation of RMFs will not be discussed here but 
are detailed in the materials and methods. Immunofluorescence was used to confirm fibroblast purity 
using the fibroblasts markers vimentin and fibronectin, as well as cytokeratin, a keratinocyte marker 
(Figure 31 in Appendix). PBMCs were isolated under sterile conditions from fresh macaque or human 
blood using Ficoll-Hypaque gradient centrifugation and stored in liquid nitrogen. At the time of the ex-
periment, PBMCs were quickly thawed, checked for viability and used immediately. For each experi-
ment, PBMCs were used from one individual macaque or human. 
To test our hypothesis we setup a co-culture system similar to what we described previously for 
human pDCs (Figure 15). RMFs and HFFs were seeded into 96-well plates, grown to sub-confluency and 
infected with B virus (MOI 5). At 1hpi, unadsorbed virus was removed and PBMCs were added to each 
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well in 200 ul medium and incubated for 23h. Simultaneously, PBMCs were seeded in 50ul of culture 
medium into 96-well round-bottomed plates and each treatment was added in 150ul of culture medi-
um. Cells were incubated at 37C, in a humidifed 5% CO2 incubator and at 24hpi cell-free supernatants 
were collected by centrifugation at 400xg for 10min. Tween/DOC was added to a final concentration of 
1% to inactivate virus. Supernatants were stored at  -80C until analyzed by ELISA to measure IFN- lev-
els using the Human IFN- pan ELISA Development Kit (HRP) (MabTech, Cincinnati, OH). This kit detects 
11 of the 12 subtypes of IFN- using a sandwich ELISA technique with a capture and a detection anti-
body conjugated with horseradish peroxidase (HRP). Serial dilutions of a standard provided with the kit 
allowed for generation of a standard curve and IFN- concentrations were interpolated using RIA 
Spline/LOWESS in GraphPad PrismTM. To ensure the functionality of the PBMCs, we used positive con-
trols known to induce IFN- from PBMCs. For human cells we used HSV-1, as this virus is endemic in 
humans as B virus is endemic in macaques, and it is a closely related simplex virus, and a robust inducer 
of IFN- from PBMCs. For macaque cells, CpG 2216 (5 g/ml), which is a synthetic DNA molecule that 
activates pDCs via TLR9, was added at 1hpi to co-cultures. CpG was used primarily because HSV-1 does 
not infect RMFs productively. As negative controls, medium only and MCL were used to measure any 
basal response(s) or to how the virus stocks were generated.  
As shown in Figure 21 Box A, B virus infected RMFs co-cultured with PBMCs (white bars) failed 
to produce significant amounts of IFN- at 11.69 pg/ml. Our positive control of CpG 2216 verified that 
macaque PBMCs in co-cultures were capable of producing IFN- with mean levels of 65 pg/ml. When 
macaque PBMCs were directly exposed (gray bars) to B virus infected lysates or CpG, each induced 24 
pg/ml proving that the PBMCs were responsive to B virus. As expected, neither of the negative controls 
induced significant levels of IFN- in co-cultures with RMFs or from direct exposure. 
Similarly and as shown in Figure 21 Box B, human PBMCs co-cultured with B virus infected HFFs 
failed to produce any significant amount of IFN- at 1.79 pg/ml, but our positive control of HSV-1 shows 
70 
that PBMCs were responsive by producing 6.48 pg/ml of IFN-. Also, human PBMCs directly exposed to 
B virus or HSV-1 infected lysates produced 46.59 pg/ml and 107 pg/ml of IFN-, respectively. The re-
sponse was virus specific as human PBMCs that were directly exposed or in co-cultures with negative 
controls did not produce significant amounts of IFN-. It is important to point out that neither human or 
macaque fibroblasts produced any detectable IFN- in response to any of the treatments (data not 
shown, Brock 2012). 
These data show that the host specific PBMC response to B virus infected fibroblasts was similar 
between human and macaques. There was a difference in the amount of IFN- produced from PBMCs 
after direct exposure to B virus infected lysates. Human PBMCs made twice as much IFN- than ma-
caque PBMCs after direct exposure. Macaques have similar numbers of pDCs in PBMCs as humans [211], 
but contain fewer mDCs [212], which may explain the observed reduction in the amount of total IFN- 
from macaque PBMCs directly exposed to B virus.  Using our correlation of human PBMC induced IFN- 
with that of pDCs, we can assume because macaques contain a similar number of pDCs at 0.1% of 
PBMCs, that the IFN- should be equivalent to human pDCs. The level of IFN- produced from macaque 
PBMCs, however, was half as much as from human PBMCs, indicating that macaque pDCs may respond 
differently to B virus, or alternatively, because they have fewer mDCs, show an overall reduction in IFN-
.   
There are limited data available on the PRRs in macaque cells as compared to human cells, but 
macaque pDCs express similar levels of TLR7/9 and IRF7 and respond to HSV-1 by producing similar lev-
els of IFN-, when measured by intracellular cytokine staining and ELISPOT [211]. These data suggest 
that macaque cells are sensing B virus or viral DNA differently than human pDCs/PBMCs. If this is the 
case, then it is crucial to understand the differences between these two hosts, especially considering 
that macaques are critical animal models for many human diseases, and with respect to this disserta-
tion, could explain the different outcomes of infection, providing a potential target for therapeutics.  
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To determine whether the amount of virus available in the supernatants of infected fibroblasts 
affected the IFN- production by PBMCs, we compared the amounts of B virus available to PBMCs in co-
cultures. To test this, HFFs and RMFs were infected with B virus (MOI 5) and B virus titers were meas-
ured in the supernatants after 24h. B virus remains primarily cell-associated through the fusion of in-
fected cells (syncytia), which limits the amount of cell-free virus within supernatants. As shown in Figure 
22, the titers in supernatants from B virus infected RMFs was 4.6x104 pfu/ml, while the titers of B virus 
in supernatants of infected HFFs was 1.8x104 pfu/ml, a 2.5-fold difference. B virus titers were much 
higher in RMFs within the cell and supernatants than HFFs, as expected. The titer of B virus iin infected 
cell lysate-exposed exposed PBMCs was 5x105 pfu/ml, approximately a log greater than in the co-
cultures. The titers of B virus in the supernatants from RMFs and HFFs were similar, and although the 
levels of IFN- produced in co-cultures were not significant, RMFs produced nearly 12 pg/ml while hu-
man cells produced only 2 pg/ml. This 3-fold reduction in virus production from HFFs may explain, in 
part, the reduction in the levels of IFN- produced from human PBMCs in co-cultures. A dose response 
study is required to quantify the ability of PBMCs to make IFN- in co-cultures. As discussed previously, 
the quality of virus produced from infected fibroblasts may be different than the virus accessible in the B 
virus infected lysates used in direct virus exposure. Additionally, and perhaps more importantly, free- 
viral DNA is likely present in the infected cell lysates, but this want not measured in our experiments to 
date.  
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Figure 21 IFN-production from B virus-exposed human and macaque PBMCs  
HFFs (human) and RMFs (macaques) were infected with B virus (MOI 5) for 1h and PBMCs were added and cultured 
for 24h (White bars). Simultaneously, human and macaque PBMCs were directly exposed to B virus infected cell ly-
sates (MOI 5), as well as to control treatments and cultured for 24h (Gray bars). Cell-free supernatants were collected, 
tween/DOC was added to a concentration of 1% to inactivate viruses and IFN- concentrations were measured by 
ELISA. UN=medium only; MCL=uninfected cell lysate; HSV-1 MOI of 5; CpG 2216 (5g/ml). Error bars represent SEM. 
*p<0.05 by ANOVA with a post-hoc of Newman-Keuls. 
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Figure 22 Infectious B virus contained in supernatants/cells of B virus infected human and ma-
caque fibroblasts 
B virus titers were measured in the supernatants (sup) and in the supernatants and cells (sup+cells) after 24 hpi to 
measure progeny virus from B virus infected (MOI 10) rhesus macaque fibroblasts (RMFs), and human foreskin fibro-
blasts (HFFs). The supernatants from HFFs contained 1.8x10
4
 pfu/ml of B virus while the supernatants from RMFs con-
tained 4.6x10
4
 pfu/ml of B virus. The virus is primarily cell-associated as shown by the titers obtained from superna-
tants together with cells at 1.3x10
5
 pfu/ml for HFFs and 1.6x10
6
 pfu/ml for RMFs. 
3.6 B virus replication is not sensitive to IFN- produced from virus exposed PBMCs 
We have here that human pDCs, as well as human and macaque PBMCs respond to direct B vi-
rus exposure with the production of cytokines and chemokines, albeit the levels of these are lower than 
those observed in parallel experiments with HSV-1. We have further evaluated in greater detail, IFN-
production by pDCs exposed to infected fibroblasts versus pDCs exposed to B virus released from in-
fected cell lysates. The levels of cytokines produced by human pDCs, or human and macaque PBMCs, co-
cultured with B virus infected fibroblasts were significantly lower than the levels in parallel experiments 
infected with HSV-1 Figures 16 and 21).  These data demonstrate that pDCs are activated by B virus 
more so in the presence of infected cell lysates, than in the presence of intact infected cells, however, 
pDCs are not activated to the extent that they are in the presence of HSV-1 under similar conditions.  To 
explore further why B virus infected cell lysates activated pDCs to a greater extent than intact infected 
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cells, we speculated that perhaps there was less virus released by the intact infected cells. An explana-
tion for the differences in pDC activation is not evident, but we have shown it is not due to limited 
amounts of virus in supernatants of infected fibroblasts (Figures 18 and 22).  IFN- is the classic antiviral 
compound and has been shown to dramatically reduce HSV-1 titers in vitro.  Animals or humans with 
defects in their ability to produce IFN- develop encephalitis as a result of HSV-1 infection, which is 
normally an innocuous infection in humans. To determine whether there was an antiviral effect of the 
IFN- produced from human and macaque PBMCs exposed to B virus released from infected cell lysates, 
we quantified the sensitivity of B virus replication to PBMC produced IFN-, with the knowledge that our 
data support that the bulk of IFN-was produced from pDCs contained within the PBMC population. 
Supernatants from B virus exposed PBMCs either directly exposed or in co-culture with B virus infected 
fibroblasts, were tested to determine whether B virus titers from infected fibroblasts were reduced. We 
hypothesized that the IFN- produced from B virus-exposed PBMCs will reduce the production of infec-
tious virus from infected fibroblasts, but because PBMC co-cultures lack significant levels of IFN- 
these will fail to reduce production of infectious B virus. To test this hypothesis, PBMCs were incubated 
with B virus contained within infected cell lysates (MOI 5) for 1 h in a minimal volume of culture medium 
supplemented with 2% FBS, after which the cell-culture medium volume was brought to 200 ul and in-
cubated. After 24 h, cell-free supernatants were collected by centrifugation at 400xg for 10 min, in 
which any adsorbed virus particles would remain with the cells. RMF and HFFs were grown to sub-
confluency in a 48-well plate and infected with B virus (MOI 5). After 1 h adsorption, the inoculum was 
removed and the supernatants previously collected from the B virus exposed PBMCs were added and 
cells were incubated for 23 h. These supernatants contained whatever IFN- was produced by the 
PBMCs in response to exposure to B virus infected cell lysates.  Infected RMFs and HFFs as well as su-
pernatants from these were collected, frozen and thawed once, and titered by standard plaque assay. 
As a control, fibroblasts were treated similarly and cultured without PBMC supernatants. As shown in 
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Figure 23, neither human or macaque B virus exposed PBMC supernatants caused a significant reduction 
in the levels of infectious virus produced from each respective cell line even in the presence of IFN- 
produced by PBMCs directly exposed to B virus (Figure 21). As shown in Figure 23A, B virus titers from 
human fibroblasts (A. left graph) at 24 hpi, following culture with supernatants harvested from B virus 
exposed PBMC (BV-exposed PBMC) were 5.4x105 pfu/ml, while HFFs treated with MCL-exposed PBMC 
(MCL-exposed PBMCs) produced 9x105 pfu/ml, a 0.6 times increase of titer, which was not significant 
when analyzed by student t-test.  Macaque fibroblasts (A. right graph) showed a similar trend, but the 
titers were a log higher than HFFs for when the medium from MCL-exposed PBMC was cultured with 
infected RMFs (MCL-exposed PBMC) at 1.2x107 pfu/ml and when B virus-exposed PBMCs medium was 
incubated with infected RMFs (B virus-exposed PBMC) there was 1.5 times reduction in titers to 8x106 
pfu/ml. B virus titers in both human or macaque fibroblasts when treated with medium from B virus ex-
posed PBMCs were not significant when compared to infected fibroblasts that were treated with medi-
um from MCL treated PBMC when analyzed using a paired two-tailed Student t-test. These data show 
that PBMCs exposed to B virus did not significantly inhibit B virus replication in spite of IFN- production 
by B virus exposed PBMCs (Figure 21). 
A more accurate representative of natural infection is to determine if supernatants from co-
cultures of PBMCs could suppress B virus replication. We did not expect B virus replication to be reduced 
when infected fibroblasts were treated with the supernatants from B virus infected co-cultures, as they 
did not produce significant amounts of IFN- (Figure 21). To test this, we infected fibroblasts with B vi-
rus (MOI 5) and at 1 hpi, we added PBMCs and cultured for 23 h. As a negative control, we MCL treated 
co-cultures at the equivalent and same way as B virus. Cell-free supernatants were collected by centrifu-
gation at 400xg for 10 min. HFFs and RMFs were grown to confluency in a 48-well plate and infected 
with B virus (MOI 5). At 1hpi, unadsorbed virus was removed and the PBMC co-culture supernatants 
were added to infected fibroblasts and cultured for 24 h. As shown in Figure 23B and as expected, B vi-
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rus titers were not significantly reduced when cultured with supernatants from B virus infected PBMC 
co-cultures. B virus titers in HFFs (B. Left graph) treated with supernatants from PBMCs co-cultured with 
B virus infected HFFs (BV PBMC Co-cultures) and MCL infected HFFs (MCL PBMC Co-cultures) showed a 
similar titer at 3.0x105 pfu/ ml. Again, the trend was conserved in macaques as the titers for RMFs treat-
ed with supernatants from B virus infected co-cultures (BV PBMC Co-cultures) or MCL treated co-
cultures (MCL PBMC Co-cultures) were the same at 3.0x106 pfu/ml, a log higher than HFFs. These data 
were what we expected because the co-cultures did not produce significant amounts of IFN-. Overall, 
these data indicate that B virus exposed PBMCs, either directly exposed to B virus, or in co-cultures with 
infected fibroblasts, fail to limit B virus replication in fibroblasts in either host. These data were unex-
pected especially for macaque PBMCs because B virus is endemic in these animals, we predicted that 
these could limit B virus replication in cells derived from the primary sites of infection. These data make 
it clear that B virus is resistant to PBMC induced IFN- in either host. 
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Figure 23 B virus exposed PBMC supernatants do not reduce B virus titers in fibroblasts 
A. Supernatants from B virus exposed PBMCs do not reduce replication in B virus infected fibroblasts. PBMCs were 
exposed to B virus (MOI 5) or MCL for 24h. The supernatants were transferred to B virus infected fibroblasts (MOI 5) 
at 1hpi and cultured for 23h and titers were measured (BV-exposed PBMC). A negative control of MCL treated PBMCs 
were used (MCL-exposed PBMC). Titers are shown in the table on the right. 
B. Supernatants from B virus infected PBMC co-cultures do not reduce B virus replication in infected fibroblasts. Fi-
broblasts were infected with B virus (MOI 5) and at 1hpi, PBMCs were added and cultured for 23h. Cell-free superna-
tants were transferred to freshly infected fibroblasts (MOI 5) and cultured for 23h and titers were determined. The 
medium from co-cultures of PBMCs with B virus infected fibroblasts was transferred to B virus infected fibroblasts (BV 
PBMC Co-cultures) and titers were measured after 24h. As a control, B virus infected fibroblasts were treated with 
MCL treated fibroblasts co cultured with PBMC (MCL PBMC Co-cultures). The tables on the right show the titers at 
each treatment.   
3.7 Sensitivity of B virus replication in infected macaque and human cells to recombinant IFN-  
To consider the possibility that B virus replication may not be sensitive to the levels of IFN- pro-
duced by PBMCs exposed to B virus infected cell lysates (46 pg/ml), we considered, with the high MOI of 
5, that the IFN pathway, overwhelmed by large amounts of virus, could not effectively block the produc-
tion of B virus progeny in newly infected cells. We hypothesized that the efficacy of the IFN-antiviral 
activity is dependent on the IFN- dose and the amount of infectious virus to which a cell is exposed. 
To test this hypothesis, we pre-treated fibroblasts with universal Recombinant Type I IFN (PBL Interferon 
Source, Piscaway, PA) at varying concentrations ranging from 12.5-50 U/ml for 30 min prior to infection. 
The IFN-treated HFFs and RMFs were then infected with B virus at a low MOI of 0.01 or high MOI of 5. 
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Unadsorbed virus was removed and cells were cultured in the presence of IFN-for an additional 23 h. 
Cells were collected by scraping into the medium followed by freeze-thawing and titering by standard 
plaque assay. The purpose of using a low MOI was to allow for a natural scenario where IFN- binds to 
bystander cells to provide some protection by blocking virus replication, whereas the high MOI was used 
to ensure maximal infection of all cells to determine whether IFN-could block de novo production of 
progeny virus. 
As shown in Figure 24, B virus replication in HFFs or RMFs was not significantly reduced, whether 
the infection was a high or low MOI, and regardless of the dose of IFN. B virus titers in HFFs infected at 
an MOI of 5, in the absence of IFN- treatment were 2x106 pfu/ml.  At the lower MOI of 0.01, HFF titers 
were reduced to 2x105 pfu/ml without IFN- treatment. Virus titers were reduced to 5x104 pfu/ml, a 4-
fold reduction, when HFFs infected (MOI 0.01) were treated with 12.5 U of IFN- but this reduction was 
not significant when analyzed by ANOVA. At 25 U and 50 U, the virus titers in HFFs at an MOI of 0.01 
were nearly the same as untreated at 1x105 pfu/ml and 3x105pfu/ml, respectively. At higher MOI 5 in-
fectiouns, infectious virus produced in HFFs, that were not treated with recombinant IFN-a, were pre-
sent at a log higher than at the lower MOI of 0.01, with a similar drop in titers in the 12.5 U IFN treated 
group at 8x105 pfu/ml, but was not significant when analyzed using ANOVA. RMF titers at MOI 0.01 and 
MOI 5, were nearly the same without IFN- treatment and at all doses of recombinant IFN-, but were 
not significantly different at 1x107 pfu/ml. We expected the amount of virus progeny to be reduced in 
response treatment of cells prior to and throughout infection with higher doses of recombinant IFN- 
particularly when infections were performed with low MOIs but the response was similar regardless of 
the amounts of recombinant IFN- and virus in both host cell species. The levels of recombinant IFN- 
in each of the treatments were much higher than we observed from our PBMCs (Figure 21). According 
to the manufacturer, PBL Interferon Source, 1 U of Universal Type I IFN has an activity of approximately 
38 pg/ml of IFN, so 12.5 U represents 475 pg/ml of IFN, which we did not observe in any of the PBMC 
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cultures, either directly or in co-cultures, however it is shown later that these low levels are sufficient to 
activate STAT-1, which is downstream of the IFNR. Even at artificially high levels of recombinant IFN-, 
B virus replication was not significantly reduced in either macaque or human cells. We expected that B 
virus titers would be lower in the natural host cells, but these data clearly show that IFN- does not 
block B virus replication.  This is an important observation suggesting that the amount of virus produced 
during infection is likely a factor in different pathogenesis outcomes in macaques and humans, but ra-
ther other controllers or lack thereof, of the effects of produced virus play more important roles in the 
differential pathogenesis observed between macaques and humans in vivo, because at least at the site 
of entry, virus replication is unfettered in the presence of PBMC produced IFN-or recombinant IFN-  
 
 
Figure 24 B virus titers are unaffected by recombinant IFN- 
Fibroblasts were pretreated with Universal Type I IFN for 30min, after which they were infected with B virus at differ-
ent MOIs. Cells were cultured for 24h with IFN and titered by standard plaque assay to quantify progeny virus pro-
duced from macaque and human fibroblasts. NS=not significant by student t-test. 
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3.8 Medium from B virus exposed PBMCs activates the Type I IFN signaling pathway in uninfected 
macaque and human fibroblasts 
We have shown that B virus titers were not reduced in HFFs or RMFs when cultured with medi-
um from B virus exposed PBMCs (Figure 23), so we wanted to know next whether IFN-produced by B 
virus exposed PBMCs (Figure 21) is functionally active and sufficient to activate the IFN-signaling 
pathway in uninfected fibroblasts. Because the titers of B virus were unaffected in the presence of IFN- 
in B virus exposed medium from PBMC exposed to B virus infected cell lysates, we hypothesized that B 
virus induced IFN-a produced by PBMCs is not functional and does not activate the IFN-signaling 
pathway in healthy fibroblasts from either macaque or human species. Under normal, healthy condi-
tions, type I IFN signaling pathway is activated upon binding of IFN-/ to the IFNR. HSV-1 has been 
shown to target the IFN receptor for degradation as a mechanism to limit the IFN response [213], but 
when HFFs and RMFs were infected with B virus (MOI 5), the IFNaR levels were not changed when com-
pared to MCL treated cells (data not shown, N. Brock, 2012). Ligand:receptor binding activates Janus 
kinases (JAK), of which there are four members (JAK1, JAK2, JAK3, and TYK) to recruit and phosphorylate 
STATs, of which there are 7 family members (STAT1-6; STAT 5a, 5b). Activated STATs then form a homo- 
or heterodimer that complex with an interferon regulatory factor to become an interferon stimulated 
gene factor (ISGF). In the case of Type I IFN signaling, the transcription factor complex is designated 
ISGF3, which is composed of a heterodimer of STAT1/2 and IRF9. The ISGF enters the nucleus via specific 
nuclear membrane transporters and binds to specific promoter regions within DNA designated interfer-
on response elements (ISRE). The trans-activating domain, located at the C terminus of the STAT mole-
cules can recruit other transcription factors and co-factors to mediate interferon-dependent gene ex-
pression. Once the genes are activated, phosphatases within the nucleus can remove the phosphate 
groups from the STATs to turn off gene transcription. The de-phosphorylated STATs are shuttled back to 
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the cytoplasm and assuming the activating signal, in our case, IFN-, is still bound to the receptor, STATs 
can be reactivated by phosphorylation via JAKs. This process continues until the activating signal is no 
longer available, or if an antagonistic molecule, such as the suppressor of cytokine signaling (SOCS), or 
the protein inhibitor of STAT (PIAS), whose expression is IFN dependent, interferes with the pathway. 
For our experiments, we used STAT-1 phosphorylation as a measure of IFN-signaling as a result of 
treatment of healthy cells with medium collected from B virus exposed PBMCs.  STAT1 can be alterna-
tively spliced to generate two isoforms, STAT1 (91kDa) and STAT 1 (84kDa). The functions of the 
splice variants are not well known, but in the context of Type I IFN signaling, the variants appear to func-
tion similarly. STAT-1 lacks the transactivation domain, which would prevent the tethering of transcrip-
tion factors after promoter binding, potentially directing a different gene expression profile than from 
that engaged as a result of STAT-1. Lodige et al reported in a study of IFN- treated HeLa cells that 
STAT1 was not different than STAT-1 in the ability to bind to the JAKs, but that the nucleocytoplasmic 
shuttling of STAT-1 was slower, and that STAT-1 was more prevalent at lower levels of IFN- [214]. 
STAT-1 can undergo numerous post-translational modifications such as glycosylation, acetylation and 
phosphorylation all of which can influence the interactions with JAKs, other STATs, IRFs, ISGF promoter 
binding, transcription factor recruitment and IFN dependent gene expression. For our purposes, we 
used the phosphorylation of STAT-1 at tyrosine 701 as a marker of activation of STAT-1 and did not ex-
plore any other modifications.  
To test our hypothesis that IFN- from PBMCs does not activate the IFN-signaling pathway we 
incubated human and macaque PBMCs with infected cell lysates containing B virus (MOI 5) for 24h. To 
confirm that the PBMCs could produce IFN-, we added CpG 2216 at 5ug/ml to healthy PBMCs, which 
subsequently can induce IFN- from pDCs in a TLR9 dependent manner. We used two negative controls 
for IFN- production from PBMCs, medium only and MCL, in equivalent amounts to the B virus exposed 
PBMCs. We cultured with PBMCs with treatments for 24h and supernatants were collected by centrifu-
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gation at 400xg for 10min. To determine if medium from the infected or control PBMCs (supernatants) 
could activate STAT-1 phosphorylation (p-STAT-1) in uninfected fibroblasts, RMFs and HFFs were grown 
to sub-confluency in 48-well plates and the cell-free supernatants transferred to uninfected fibroblasts. 
As a positive control for p-STAT-1, we treated uninfected fibroblasts with 50 U/ml of recombinant IFN-
. At specific times, medium was removed and cells were collected in 50ul of Laemmli buffer containing 
2- -mercaptoethanol and the samples were stored at -80°C.  To determine if STAT-1 was phosphory-
lated, an SDS gel was run using 7.5% polyacrylamide, with equal loading by volume of the cell lysates 
(which was confirmed by using GAPDH as a loading control). Subsequently, the proteins were electrob-
lotted onto nitrocellulose (0.45 m), blocked and then probed using anti-phospho (Y701)-STAT-1, total 
STAT-1, and GAPDH as a loading control.  As shown in the left box of Figure 25, human fibroblasts treat-
ed for 1h with medium collected from B virus exposed PBMCs did activate-STAT-1 via phosphorylation, 
demonstrating that the levels of IFN-were sufficient to initiate this pathway. As discussed previously, 
STAT-1 can be alternatively spliced to produce two isoforms, and HFFs exposed to medium collected 
from B virus exposed PBMCs resulted in the p-STAT-1/ present at similar levels. Our positive control 
of CpG treated PBMCs, also induced p-STAT-1 and  within 1 h post treatment, similarly to HFFs treat-
ed with medium from B virus exposed PBMCs. Although our MCL treated PBMCs failed to produced any 
detectable levels of IFN- (Figure 21), we saw very weak p-STAT-1 Our positive control of IFN treated 
HFFs, resulted in activation of both isoforms but levels of p-STAT-1 were greater. At 3 h following ex-
posure to medium from B virus exposed PBMCs, HFFs showed a higher intensity band for p-STAT-1 
relative to what was observed at 1 h post treatment. The p-STAT-1levels for MCL were unchanged at 3h 
and the IFN--treated fibroblasts showed a reduction in intensity of p-STAT-1with theisoform 
much weaker than observed in the samples collected at 1h. An interesting observation is that while all 
total STAT-1 levels were equivalent across samples, HFFs only expressed STAT-1for total STAT-1. These 
results indicate that human PBMCs exposed to B virus can activate the IFN- signaling pathway and that 
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B virus induces the expression of the STAT-1  isoform. The major producer of IFN-in PBMCs, are 
pDCs. 
To compare the macaque response, as shown on the right box in Figure 25, macaque PBMCs ex-
posed to B virus infected cell lysates were able to induce p-STAT-1 in uninfected RMFs at 1h, and un-
like humans did not induce the  isoform.  Our negative control of MCL induced a low amount p-STAT-
1 and our positive control of CpG treated PBMCs induced low levels of p-STAT-1 RMFs treated with 
IFN-induced both isoforms of p-STAT-1, although the  isoform was present at higher levels, where 
HFFs only induced the  isoform. There was an apparent delay the appearance of p-STAT-1, as the in-
tensity of the band was greater at 3h post treatment than at 1 h for RMFs. The medium collected from 
CpG-treated PBMCs failed to increase the levels of p-STAT-1 at 1 h and only activated the  isoform. The 
IFN-treated RMFs showed a greater intensity of the p-STAT-1 band at 3 h and additionally activated 
the  isoform. Interestingly, RMFs appear to have a basal level of STAT-1 that is not present in HFFs as 
total levels of STAT-1 of both isoforms were equal. This is a crucial observation because while there are 
limited data on the functions of the different isoforms, it is clear that RMFs and HFFs respond differently 
to IFN-stimuli, and treatment with medium from B virus exposed PBMCs resulted in differential activa-
tion of STAT-1 isoforms in HFFs and RMFs. While we have shown that both macaque and human PBMCs 
produce IFN- in response to B virus (Figure 21), we have shown here that the IFN- in medium from 
these activates the IFN- signaling pathway in uninfected cells (Figure 25). We know that B virus replica-
tion is unaffected by medium collected from B virus exposed PBMCs (Figure 23), but the differential ac-
tivation of STAT-1 isoforms between species will be explored in the near future as these differences may 
result in dramatic differences in IFN-dependent gene expression in each host. This differential effect will 
potentially inform differences in the pathogenesis of B virus infection in macaques and humans, and can 
be partially investigated in co-culture model systems in the absence of adequate small animal models.  
Data from such studies can provide insight into potential transgenic animals that may provide in vivo 
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models to study B virus infections with pathogenesis patterns similar to those observed in infected ma-
caques or humans.     
             
 
Figure 25 Medium from PBMCs exposed to B virus activates Type I IFN signaling in uninfected 
fibroblasts 
Fibroblasts derived from macaques and humans were cultured with medium collected from B virus exposed PBMCs 
for 1 and 3h. Fibroblast lysates were collected in 50 ul and run on a 7.5% SDS-polyacrylamide gel, transferred to a ni-
trocellulose membrane and probed for p-STAT-1 and total STAT-1, as well as for housekeeping protein GAPDH 
Sup=supernatant (medium), MCL= mock cell lysate, BV: B virus, IFN=recombinant IFN-50U/ml, CpG= CpG 2216 
5g/ml  
3.9 Cell-culture medium from PBMCs co-cultured with B virus infected human or macaque 
fibroblasts activates Type I IFN signaling pathways in uninfected fibroblasts of each respective 
species  
We showed previously that PBMCs co-cultured with B virus infected fibroblasts do not produce 
significant amounts of IFN- and that co-culturing infected fibroblasts with medium from these PBMCs 
did not reduce B virus replication. To explore a possible mechanism of B virus resistance to IFN- in fi-
broblasts in light of the observations that co-cultures failed to produce significant amounts of IFN-, we 
hypothesized that medium from PBMCs co-cultured with B virus infected fibroblasts fails to activate 
the IFNR signaling pathway. We predicted that medium from these co-culture models representing 
interactions in humans or macaques at the site of infection would fail to induce STAT-1 activation, or p-
STAT-1, because the IFN- levels were not significant when compared to mock cell lysate treated co-
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cultures (Figure 21). To test this hypothesis, we infected fibroblasts with an MOI of 5 of B virus. At 1 hpi, 
we added PBMCs and incubated these co-cultures for an additional 23 h. The cell-free medium was 
transferred to uninfected fibroblasts and incubated for 1h. Treated uninfected fibroblast lysates were 
prepared and analyzed by western blot assay to assess total STAT-1 and p-STAT-1 relative levels. As a 
negative control, medium collected from MCL treated PBMC co-cultures were used to ensure the IFN- 
production and subsequent p-STAT-1 was due to virus, not to cell lysate. Two positive controls were 
used, one, which was CpG 2216 (5g/ml), to ensure the PBMCs in co-cultures could induce IFN-, and 
the second positive control was Universal Recombinant Type I IFN, which was added to the uninfected 
fibroblasts to ensure that the fibroblasts were capable of activating the IFNR signaling pathway.  As 
shown in Figure 26, medium from human PBMCs co-cultured with B virus infected human fibroblasts 
activated STAT-1, indicating that the IFN- released into medium from B virus infected co-cultures was 
sufficient to activate the IFN pathway. Our positive control for IFN- production, CpG 2216, also activat-
ed STAT-1 in human cells, leading us to assume that IFN- was the activator of STAT-1 in this experi-
ment. We did see, however, that medium from mock cell lysate treated PBMCs co-cultured with infect-
ed fibroblasts activated STAT-1. As we showed in Figure 25, medium from PBMCs treated with mock cell 
lysate and co-cultured with B virus infected fibroblasts also produced IFN- which activated STAT-1, as 
confirmed in this experiment. Later studies, using a multiplex assay for 26 human chemokines and cyto-
kines, showed that human PBMCs treated with MCL and co-cultured with B virus infected HFFs, pro-
duced significant levels of IL-6 (data not shown, M. Vasireddi), which is also known to activate STAT-1 B 
virus exposed human PBMC co-cultures also induced IL-6, but the levels were lower than those pro-
duced by PBMCs treated with mock cell lysates. The results from this experiment, indicate that the me-
dium from human PBMC co-cultures with B virus infected human fibroblasts activate STAT-1, and thus 
the IFN-pathway in uninfected human cells, but the activation is most likely due to the high amounts 
of IL-6 in the supernatants, not the low levels of IFN- present in this particular treatment group.  
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The macaque response is quite different from the human response, in that the supernatants 
from macaque PBMCs co-cultured with B virus infected fibroblasts activated STAT-1 poorly. In contrast 
to humans, the supernatants from MCL treated co-cultures did not induce any STAT-1 activation leading 
to the conclusion that macaque PBMCs are not activated by cell lysates. The cell lysates in all of our ex-
periments were produced using Vero cells, which were also used to produce all B virus and HSV-1 used 
in the experiments described in this dissertation.  It is possible that since African Green Monkeys from 
which Veros are derived, are not sensed as foreign activating stimuli, because these Old World Monkeys 
are more closely related evolutionarily to macaques.  To rule this out, additional experiments will be 
performed in the near future with virus and lysates prepared from human and macaque fibroblasts.  But 
these results hint at the possibility that under the experimental conditions, macaque cells did not pro-
duce IL-6, but this will be evaluated again in additional experiments in the near future, not as part of this 
dissertation. Our data show that RMFs respond to IFN- through the activation of STAT-1, albeit only 
weakly under the experimental conditions established. The positive control for IFN- production from 
PBMCs, CpG 2216, led to only faint activation of STAT-1(Figure 26), which was not expected since our co-
cultures with CpG 2216 induced greater levels of IFN- than did B virus co-cultures (Figure 21). The faint 
bands for both B virus and CpG 2216 may be due to the short treatment interval, but additional experi-
ments will be required to evaluate this further. In Figure 25, we showed that RMFs had a higher intensity 
band for STAT-1 at 3h than at 1h, indicating that the temporal control of the signaling pathway in RMFs 
may be different from that in HFFs. Because we measured STAT-1 activation at 1hpe by PBMC so-culture 
medium shown in Figure 26, we can hypothesize that the activation of STAT-1 would be increase at 3h.  
The co-culture model system we have used for these experiments is a great tool for understand-
ing how B virus infection modulates host immune responses at a cellular level, but these studies must be 
extended to evaluate multiple cell types and their interactions in a complex defense system. Our data 
provide for the first time knowledge that IFN-is produced from pDCs, and that PBMCs can be used in 
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their place when reagents are lacking for the enrichment of pDCs in species, e.g., macaques and other 
nonhuman primates.  We also now understand that the produced IFN-activate IFNR signaling path-
ways in human and macaque fibroblasts, each which are critical cells at the site of virus entry, but to 
what extent and how these pathways are modulated downstream remains to be investigated in future 
studies to unravel the impact of  this pathway on the pathogenesis of natural and zoonotic infection .  
 
 
 
 
Figure 26 Supernatants from PBMC co-cultures activate Type I IFN signaling in uninfected fi-
broblasts 
Fibroblasts were cultured with supernatants from PBMC co-cultured with B virus infected fibroblasts for 1h. Cell ly-
sates were collected in 50ul and run on a 7.5% polyacrylmide gel, transferred to a nitrocellulose membrane and 
probed for p-stat1. Sup=supernatant, MCL=mock uninfected mock cell lysate, BV: B virus, IFN=recombinant IFN 
50U/ml, CpG= CpG 2216 5g/ml  
 
 
3.10 B virus infection of macaque and human fibroblasts does not activate or block Type I IFN 
signaling 
In an effort to understand the resistance of B virus to the effects of IFN-, derived from either 
PBMC supernatants, PBMC co-cultures or recombinant IFN- treatment during low or high MOI infec-
tions across a range of IFN-doses, we then hypothesized that B virus blocks the Type I IFN signaling 
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pathway in fibroblasts. The type I IFN receptor is activated upon binding by either IFN- or IFN-
leading to the activation of JAK and STATs. We used the phosphorylation of STAT-1 as a measure of 
IFNR ligation and signaling activation. In the first experiment, we addressed the question of whether B 
virus activated, either directly or indirectly, the Type I IFN pathway in RMFs or HFFs. We know that nei-
ther RMFs nor HFFs produce Type I IFNs during B virus infection, so we predicted that B virus infection in 
these cells does not result in the activation of STAT-1. To test this hypothesis, we infected fibroblasts in 
T25 flasks with an MOI of 5 for 24 h.  We collected both the supernatant and infected cells at 0, 2, 4, 6 
and 24h to measure both IFN- production and STAT-1 phosphorylation (p-STAT-1). As predicted, at all 
times post-infection, B virus did not activate the type I IFN signaling pathway through p-STAT-1 in either 
RMFs or HFFs (Figure 27). As a negative control, we exposed fibroblasts to uninfected mock cell lysates, 
which also did not induce p-STAT-1. Additionally, we measured total-STAT-1 levels to ensure the pres-
ence of STAT-1 protein in B virus infected lysates and to confirm that B virus did not degrade STAT-1 
(Figure 27). 
 
Figure 27 B virus infection does not activate Type I IFN signaling in human or macaque fibro-
blasts 
Fibroblasts were infected with B virus (MOI 5) in 24-well plates. Cell lysates were prepared and collected in 50ul 
Laemmli buffer and electrophoresed on a 7.5% SDS-polyacrylamide gel, transferred to a nitrocellulose membrane and 
probed for total STAT-1, p-STAT-1, and GAPDH. MCL=mock uninfected mock cell lysate BV: B virus MOI of 5 
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Our data so far, indicates how B virus titers are not affected by IFN- present in medium from 
PBMCs exposed to B virus infected lysates (Figure 23) or to recombinant IFN- treatment (Figure 24). In 
an effort to explore the mechanism that B virus titers are not affected by IFN-, we hypothesized that B 
virus blocks IFN signaling by blocking the activation of STAT-1 in fibroblasts. To test this hypothesis, we 
infected human and macaque fibroblasts in 24-well plates with B virus at an MOI of 5 and after 1 h ad-
sorption we added 500 U/ml of recombinant type I IFN for 30 min. The cells were lysed and collected for 
analysis by western blot assay for the presence of total STAT-1, p-STAT-1, and GAPDH. As a negative 
control, MCL treated cells were used and for a positive control for p-STAT-1 activation, mock cell lysate 
treated cells were also treated with recombinant type I IFN (500 U/ml). The data from representative 
experiments, shown in Figure 28, indicate that B virus does not block the activation of STAT-1 by the 
added recombinant IFN-, as levels were equivalent between MCL and B virus infected cells treated 
with IFN, but IFN-is not produced in mock or B virus exposed fibroblasts. Recombinant IFN treatment 
increased total STAT-1 levels in both B virus infected cells and mock infected cells. GAPDH was used as a 
loading control and was equivalent across all samples. These data show that B virus did not block the 
activation of the type I IFN pathway in human or macaque fibroblasts. Previous data from our lab indi-
cate that the interferon stimulated gene expression is not increased during B virus infection in HFFs 
[215], providing further confirmation of our results showing B virus resistance to IFN- treatment. Based 
on these data, we can hypothesize that B virus blocks the IFN signaling pathway downstream of STAT-1 
activation, and most certainly it is necessary to compare ISG expression in macaques because of the dif-
ferential activation of STAT-1 isoforms.  
90 
 
Figure 28 B virus does not block the activation of the Type I IFN signaling pathway in macaque 
or human fibroblasts 
Fibroblasts were infected with B virus at an MOI of 5 for 1h then treated with 500U/ml of IFN for 30min. Cell lysates 
were prepared and collected in 50ul of Laemmli buffer and run on a 7.5% SDS-polyacrylamide gel, transferred to a ni-
trocellulose membrane and probed for p-STAT-1, total STAT-1 and GAPDH.MCL=mock uninfected mock cell lysate, 
BV= B virus, +IFN w= 500U/ml IFN for 30 min  
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4 CONCLUSIONS 
B virus, a simplex virus closely related to HSV-1, is endemic in macaques of all species and is ca-
pable of causing fatal zoonotic infection in humans in up to 80% of cases, if not treated quickly enough 
after infection. Identifying the immune correlates of infection in both the natural and foreign hosts will 
allow us to develop therapeutics and prophylaxis against B virus infection. This dissertation aimed to 
address the defect in human immune responses to B virus infection, specifically the interferon response 
and the role(s) of pDCs during infection. Based on the observations that zoonotic B virus infection results 
in a delayed or ineffective immune responses and the knowledge of the importance of the IFN pathway 
in virus infections, we hypothesized: B virus modulates the IFN response during zoonotic infection by 
blocking plasmacytoid DC activation and subsequent IFN signaling pathways to circumvent host de-
fenses, while these pathways remain intact in the macaque hosts. 
The results from this dissertation disprove my hypothesis as shown by the data, for the first 
time, that human and macaque PBMCs produced similar amounts of IFN- in response to direct B virus 
exposure, however, IFN- production was significantly reduced when human pDCs (and PBMCs) were 
co-cultured with B virus infected fibroblasts as well as for macaque PBMCs co-cultured with B virus in-
fected fibroblasts, as currently there are no reagents available for the isolation of pDCs from macaques.  
Further, both human and macaque fibroblasts continued to support B virus replication when treated 
with IFN-, either from endogenous (B virus-exposed PBMCs) or exogenous (recombinant IFN) sources 
despite the activation of the IFN signaling pathway. We know that following B virus entry, virus repli-
cates in dermal and epidermal layers of skin or mucosa.  It has been shown by other laboratories, that 
limiting the amount of virus production at the entry site reduces the amount of virus that subsequently 
enters sensory nerve endings in the skin, thereby reducing the amount of virus that reaches the dorsal 
root or cranial ganglia sub-serving the area of entry.  My studies were undertaken to identify whether 
there were differences between the responses of human pDCs and human and macaque PBMCs that 
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can migrate into the damaged tissues and whether/how these differences affected the amounts of virus 
produced. 
Although the data presented in this dissertation disproved the hypothesis, these data contribute 
to the understanding of the pathogenesis of B virus in both natural and foreign host cells by showing 
that the IFN pathway is not differentially modulated in these hosts. Future studies are essential to un-
derstand the mechanism by which B virus is resistant to IFN because knowledge of this mechanism will 
direct the identification of therapeutic targets. We showed that immune cells produce IFN- in response 
to B virus and that B virus does not block the activation of IFN-pathways, therefore additional studies 
are needed to explore how this IFN influences the overall host response to B virus or if the B virus re-
sistance to IFN is limited to cells isolated from primary sites of infection. IFN- activates other innate 
and adaptive immune cells and may play a critical role in B virus pathogenesis in the nervous system as 
well as at peripheral sites. The delay or blockade of the production of neutralizing antibodies during ul-
timately fatal zoonotic infections is clearly one role that is distinctly different in humans and macaques.  
The impact of my findings must be studied further with respect to IFN-activation of CD4 T cells and the 
resultant activation of B cells capable of producing these neutralizing antibodies.  Additional studies are 
needed for understanding the mechanism of restricted production of IFN- during co-cultures of both 
human and macaque cells, since this may be a target for modulation of immune responses within the 
foreign host. Activation of pDCs with viral DNAs, such as those likely released in infected cell lysates, 
may serve to increase the levels of IFN-to activate key adaptive immune responses. 
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Figure 29 Working model of the role of pDCs in B virus infection  
As a summary of this dissertation, our data support the model that if pDCs could gain access to infected peripheral 
skin via a bite or a scratch from an infected monkey, they would respond to B virus infected fibroblasts with the pro-
duction of cytokines and chemokines. These cytokines would recruit and activate a number of immune cells, including 
monocytes, T cells, NK cells and other dendritic cells. Previous data from our lab showed that mDCs did not produce 
cytokines in response to B virus infected fibroblasts (**R. Abraham, M. Vasireddi et al., 2012, unpublished raw data), 
nor were NK cells functional as shown by their lack of production of perforin and granzyme (* M. Vasireddi et al., 
2010, in preparation), indicating B virus specific modulation of immune responses. Furthermore, this dissertation has 
shown, that despite the production of cytokines, specifically IFN-, B virus replication was not reduced in fibroblasts. 
These cytokines likely influence the microenvironment of immune cells in the infected skin, which may affect the ac-
cessibility of B virus to peripheral neurons or the rate at which it can enter, which may be more critical for survival 
against B virus infection than the levels of B virus replication at peripheral sites.  
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6 APPENDIX 
 
Figure 30 Donor response to CpG 
To determine if different donors had a differential response to CpG, we isolated pDCs from two different donors on 
two different days. We also pooled the pDCs to determine if heterologous populations of pDCs would affect IFN-
production in pooled pDCs. pDCs were isolated from PBMCs and cultured with CpG at 10ug/ml for 24h. Superna-
tants were collected and analyzed for IFN- production by ELISA. The concentrations of IFN- differed between do-
nors and differed by day in one donor. As expected, pooling of pDCs did not affect IFN-, but instead was an average 
of the combined donor pDC IFN- production.  
 
Figure 31 Verification of fibroblast isolation and purity from macaque whole skin biopsies 
Fibroblasts were seeded into 8 well chamber slides and grown for 2 days. Cells were fixed with methanol, blocked 
with 10%NGS and labled with anti-vimentin (green; left), -fibronectin (green; center) and –cytokeratin (red; right). 
Nuclear stain was Hoescht (blue). RMFs were positive for vimentin and fibronectin, confirming fibroblast lineage but 
negative for cytokeratin, indicating a lack of keratinocyte contamination. 
 
  
 
122 
 
 
Figure 32 B virus kinetics in macaque and human fibroblasts 
Fibroblasts were infected with B virus at an MOI of 10 in 24 well plates. Cell lysates were collected by scraping at 0, 1, 
4, and 24hpi and stored at -80C. Samples were titrated by standard plaque assay. Red line=supernatants only, black 
lines=supernatants and cells. Error bars represent SEM. 
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Table 4 Raw data for B virus exposed pDCs of cytokine and chemokine production 
Raw data for Luminex data presented in Figures 14 and X.15U=untreated, M=mock treated; B=B virus; H=HSV-1; 1, 2, 
3 represent repeat wells. Black: below detection; blue: detectable range; red: above detection 
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Table 5 Raw data for pDC cytokine and chemokine production in co-cultures 
Raw data for Luminex data presented in Figures 16 and 17. U=untreated, M=mock treated; B=B virus; H=HSV-1; 1, 2, 3 
represent repeat wells. Black: below detection; blue: detectable range; red: above detection 
 
 
 
 
